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Souhrn (abstract in Czech)
Dilatační kardiomyopatie (dilated cardiomyopathy, DCM) je druhou nejčastější
příčinou srdečního selhání. Patofyziologie DCM není zcela objasněna. Jedním
z důvodů jsou limitace současných klinických metod pro výzkum tohoto onemoc-
nění. Cílem této práce bylo posudit schopnost magentické rezonance srdce (cardio-
vascular magentic resonance, CMR), s využitím moderních zobrazovacích technik,
pro in vivo vyšetření některých klíčových patofyziolgických mechanizmů, které
mají s DCM přímou souvislost. Dalším cílem práce bylo pousoudit, zda pato-
logické nálezy na CMR umožní předpovědět klinicky relevantní zlepšení morfo-
logických a funkčních parametrů levé komory srdeční – reverzní remodelaci (left
ventricular reverse remodelling, LVRR).
U 44 pacientů s nově manifestovanou DCM (délka trvání <6 měsíců) byla prove-
dena CMR, endomyokardiální biopsie, zátěžové vyšetření a vyšetření srdečních
biomarkerů. CMR byla zopakována po 12 měsících klinického sledování.
U 34% pacientů byly pomocí biopsie zjištěny zánětlivé změny myokardu. LVRR
byla po 12 měsícech pozorována u 45% pacientů. Přítomnost pozdního sycení
gadolinia (late gadolinium enhancement, LGE) v levé komoře byla senzitivním
ale málo specifickým znakem zánětu myokardu, protože přítomnost LGE byla
taktéž projevem hemodynamického zatížení při srdečním selhání. Rozsah LGE
byl nezávislým prediktorem LVRR a taktéž prediktorem závažných klinických
událostí. Přítomnost perikardiálního výpotku a zvýšené časné sycení gadolina
byly specifickými ale málo častými známkami zánětu myokardu. Vyšetření edému
myokardu pomocí T2-vážených sekvencí nebylo přínosné pro detekci zánětu myokardu,
avšak ukázalo se užitečné pro predikci LVRR.
Lze tedy uzavřít, že CMR se jeví jako suboptimální metoda pro detekci zánětu
myokardu u pacientů s nově manifestovanou DCM. Nicméně, u těchto pacientů
může CMR odhalit poškození myokardu v souvislosti s hemodynamickým za-
tížením a navíc umožňuje spolehlivě predikovat LVRR.




Dilated cardiomyopathy (DCM) is the second leading cause of heart failure. The
pathophysiology in DCM is still poorly understood, partly because of currently
limited research tools. We investigated whether cardiovascular magnetic resonance
(CMR), using novel imaging techniques, could be used for in vivo assessment of
some key pathophysiological mechanisms related to DCM. In addition, we evalu-
ated whether the pathological findings on CMR would predict clinically relevant
functional and morphological improvement of the left ventricular (LV) function –
the left ventricular reverse remodeling (LVRR).
CMR together with endomyocardial biopsy, echocardiography, cardiopulmonary
exercise testing and a thorough assessment of cardiac biomarkers was performed
in 44 patients with new-onset DCM (<6 months of duration). The imaging was
repeated after 12 months of clinical follow-up.
Endomyocardial biopsy revealed myocardial inflammation in 34% of the pa-
tients. LVRR at 12 months occurred in 45% of the patients. Presence of late
gadolinium enhancement (LGE) in the left ventricle was a sensitive but unspecific
sign of myocardial inflammation because it was also a feature of hemodynamic
stress related to the heart failure. The baseline extent of LGE was an indepen-
dent predictor of future LVRR and also a predictor of adverse clinical events.
Pericardial effusion and increased early gadolinium enhancement were specific but
uncommon signs of myocardial inflammation. Assessment of myocardial edema by
T2-weighted imaging did not add value to detection of myocardial inflammation
but it was valuable for predicting of LVRR.
In conclusion, CMR seems a suboptimal method for detection of myocardial
inflammation in new-onset DCM. However, in these patients CMR may reveal
myocardial injury related to hemodynamic stress and it may predict future LVRR.
Key words: pathophysiology, cardiomyopathy, myocardial inflammation, reverse
remodeling, cardiovascular magnetic resonance
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1 Introduction
1.1 Scope of the problem
Dilated cardiomyopathy (DCM) is a heart disease in which the left ventricle (LV)
becomes dilated, thin-walled and dysfunctional. The reduction of the LV stroke
volume typically manifests with heart failure. In fact, DCM is after the coronary
artery disease the second leading cause of chronic heart failure with a prevalence
of 40-50/100,000 in the adult population (Mosterd & Hoes 2007).
Although the LV function may improve or even fully recover in some individuals,
the overall prognosis of the patients with DCM remains poor (Merlo et al. 2014).
A heart transplantation or implantation of a ventricular assist device are often the
only therapeutic options (Baldasseroni et al. 2002).
Etiology of DCM is multifactorial and often difficult to establish in clinical prac-
tice, even with contemporary diagnostic methods. Consequently, pathophysiology
of the disease is still poorly understood (Elliott et al. 2008). However, a better
recognition of the underlying pathophysiology is a critical prerequisite for devel-
opment of new more specific therapeutic approaches and also for individualization
of the management of DCM patients (Frustaci et al. 2009).
The lack of understanding of the pathophysiology in DCM may be largely
explained by the limitations of the currently available methods for investigating
important pathological processes in vivo (in particular myocardial inflammation
and fibrosis). This motivates the researchers to search for more reliable diagnostic
tools. Ideally, such method would not only provide insights in the pathophysiology
of DCM but it could be applied also to the daily clinical practice. In this regard,
cardiovascular magnetic resonance (CMR) using novel imaging techniques holds
promises (Friedrich et al. 2009), but its role in DCM remains to be clarified.
1.2 Etiology of dilated cardiomyopathy
As indicated above, DCM is etiologically a heterogeneous disease, even though
it presents with an invariable morphological phenotype. The diagnosis of DCM
can be established only after excluding coronary artery disease, severe arterial
hypertension, primary valve disease or a congenital heart condition as possible
causes of the ventricular dysfunction (Richardson et al. 1996, Elliott et al. 2008).
Table 1 provides an overview of the etiological factors which have been related to
the disease.
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Table 1: Etiological factors associated with DCM
Familial forms of DCM Acquired forms of DCM
Familial, unknown gene Myocarditis
– Infectious (viruses, bacterias, protozoa)
Mutation of sarcomeric proteins – Toxic
– β-myosin heavy chain – Autoimmune
– Cardiac myosin binding protein
– Troponin I Kawasaki disease
– Troponin T
– α-tropomyosin Eozinophilic (Churg-Strauss) syndrome
– Essential myosin light chain
– Actin Cytotoxic
– α myosin heavy chain – Alcohol
– Titin – Amphetamines, cocaine
– Troponin C – Doxorubicin
– Bleomycin
Genes for Z-band proeins – 5-Fluorouracyl
– Muscle LIM protein
– TCAP Nutritional diseases
– Selenium
Cytoskeletal genes – Thiamine
– Dystrophin – Carnitine
– Desmin – Hypocalcaemia
– Metavinculin – Hypophosphataemia
– Sarcoglycan complex
– CRYAB Metabolic diseases
– Epicardin
Endocrine diseases
Genes for nuclear membrane proteins
– Lamin A/C Sarcoidosis
– Emerin
Tachycardic cardiomyopathy







Adopted from Elliott et al. (2008)
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A systematic cardiologic screening may reveal DCM in a first-degree relative in
30–35% of the DCM patients (Hershberger et al. 2009). But a particular genetic
cause cannot be identified in up to two thirds of the familial cases of DCM, despite
ever-increasing availability of the next generation sequencing methods. The most
common genetic defects include truncating mutations of titin (25% of familial
and 18% of sporadic cases) and mutations of lamin A/C (4–8%), followed by
various rare mutations of genes coding proteins of sarcomere, Z-disc, cytoskeleton,
nuclear envelope, mitochondria, sarcoplasmic reticulum, metabolic pathways and
transcription factors (Lopes & Elliott 2013).
Acquired forms of DCM have been associated with a number of toxic agents,
metabolic and endocrine disease. Above all, the far most common etiology of an
acquired DCM is myocarditis, which can be found in about one third of the DCM
patients (Kawai 1999). Impairment of the ventricular function may result either
from direct myocyte injury by an infectious agent (usually by a virus), or the
otherwise benign agent may merely trigger a pathological autoimmune response
(Kawai 1999, Caforio & Iliceto 2008). If the DCM develops in the presence of
myocarditis the disease is called inflammatory DCM. Often no specific cause can
be determined – in that case the DCM is called idiopathic (Richardson et al. 1996).
Disclosing the etiology of DCM in an affected individual may be clinically im-
portant. It may provide an opportunity for applying an etiology-specific therapy
on top of the standard management of heart failure. For example, an early im-
plantation of a cardioverter-defibrillator for primary prevention of sudden cardiac
death is recommended in DCM patients with pathogenic mutation of lamin A/C,
because they have a high risk of malignant arrhythmias (Pasotti et al. 2008). Iden-
tification of familial forms of DCM enables to initiate an appropriate treatment in
affected relatives. Selected patients with myocarditis can be treated with antiviral
agents, antibiotics (Lyme carditis) or immunosuppressive treatment. Corticos-
teroids may be effective for treatment of cardiac sarcoidosis. At last, specific
treatment exists also in DCM that is associated with some rare metabolic diseases
(hemochromatosis) and endocrine disease (hypothyroidism).
1.3 DCM and left ventricular reverse remodeling
DCM involves changes in cardiac structure, myocardial composition and multiple
functional alterations at the cellular level, all of them contributing to the pro-
gressive LV dilatation and dysfunction (Koitabashi & Kass 2012). The process of
stopping and reverting these changes (either naturally or with treatment) is com-
monly known as left ventricular reverse remodeling (LVRR). More strictly, LVRR
refers to an increase of the LV ejection fraction which is accompanied by reduction
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of the LV enddiastolic volume (Koitabashi & Kass 2012). From a clinical perspec-
tive, occurrence of LVRR is important because it forecasts a favorable long-term
prognosis (Pasotti et al. 2008). Thus, achieving the LVRR by any effective means
in an affected individual belongs to the main objectives in the management of
DCM.
In contrast to the clinical evidence confirming the central role of LVRR in a
successful treatment of DCM, far less is known about the underlying pathophysi-
ological mechanisms of this phenomenon. The LVRR in DCM has been explained
either by the resolution of the underlying pathological process—such as healing of
myocarditis—or by the beneficial effect of the pharmacotherapy. However, indi-
vidual contribution of each of these mechanism is unknown.
For research of LVRR, patients with new-onset DCM (<6 months of duration)
seem to be a particularly interesting subpopulation of DCM. LVRR occurs in up
to a half of these patients, though a full LV recovery is uncommon (Dec 2014,
Bello et al. 2011). In contrast, in chronic DCM (>6 months of duration) LVRR
is less frequent and the LV dysfunction is often permanent. Moreover, the initial
insult may not be present at a later phase of the disease (Friedrich et al. 1998).
For the reasons above this work focused primary on the subgroup of the new-onset
DCM.
1.4 Current „golden standard“ method for assessment of
myocardial tissue pathology in clinical practice
Endomyocardial biopsy (EMB) is currently regarded the „golden standard” method
for in vivo assessment of myocardial tissue characteristics in cardiomyopathies.
The bioptome is usually introduced into the right ventricle through a transjugular
or transfemoral approach. Myocardial samples (5-8 pieces, each of them about
1mm3 large) are harvested from the right side of the interventricular septum.
Histopathological and immunohistochemical assessment of the specimens enables
to detect a number of tissue processes, including the presence and activity of
inflammatory cells, extent of myocyte necrosis and interstitial replacement fibro-
sis (Loud & Anversa 1984, Frustaci et al. 2009). In addition, the EMB can re-
veal a specific cause of the heart failure, such as sarcoidosis, or a storage disease
(hemochromatosis, amyloidosis, glycogenosis or Fabry disease).
However, EMB has several noteworthy limitations. First, due to its inva-
sive character the procedure carries a non-negligible risk of serious complications.
These include pneumothorax, cardiac tamponade and life-threatening arrhythmias
(Cooper et al. 2007). Second, EMB is limited by sampling bias – focal pathologi-
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cal processes may be missed if the specimens were harvested from a distant site.
The sampling bias can be partially overcomed by obtaining additional samples,
by obtaining samples from inside of the LV cavity or by targeting the biopsy to a
site which appeared pathological on a preceding imaging modality (Hauck et al.
1989, Chow et al. 1989, Shirani et al. 1993). However, such alternative approaches
increase the risk of procedural complications. At last, EMB is limited by a sub-
stantial inter-indiviudal variablity in the interpretation of the specimens (Shanes
et al. 1987). Immunohistochemistry provides a more detailed information about
the tissue pathology but its use is restricted by availability, high cost and lack of
standardization of diagnostic criteria.
1.5 The potential of CMR
CMR is a versatile and widely-available imaging modality, which does not expose
the patient to any radiation. Besides detailed assessment of cardiac morphology
and function, the imaging enables to directly visualize some key pathological my-
ocardial tissue processes that have a verified histological and pathophysiological
correlate. These include edema, hyperemia, capillary leakage, myocardial necrosis
and interstitial fibrosis (Friedrich et al. 2009).
Since its introduction into clinical practice CMR has been used mainly for
evaluation of myocardial viability in the patients with ischemic heart disease.
However, recent advances in the CMR technology and imaging techniques allowed
to extend this modality also to other, more refined applications. The following
paragraphs describe in details the main diagnostic targets for CMR and their
application in in the context of DCM.
1.5.1 Ventricular morphology and function
Cardiac morphology and function is usually assessed by so-called “kinetic” se-
quences. The main advantage of these scans are an excellent image contrast and a
high temporal and spatial resolution. These assets enable an accurate and highly
reproducible quantification of morphological and functional parameters of the left
and right ventricle. The high reproducibility of the volumetric measurement is
particularly important for serial evaluation of changes in the LV volume during
the course of the disease.
Although in DCM the LV dilatation and systolic dysfunction is not specific for a
particular etiology, transient LV wall abnormalities along with a transient increase
in LV mass can serve to retrospectively confirm resolving myocardial inflammation
(Hiramitsu et al. 2001, Zagrosek et al. 2009).
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At last, thanks to the high pixel resolution of the images, CMR often reveals
a specific morphological phenotype, which would be otherwise missed by another
imaging modality. As an example, a finding of excessive trabeculation of the LV
endocardium is specific for non-compaction cardiomyopathy (Virtova et al. 2013).
1.5.2 Pericardial effusion
Pericardial effusion may occur in a number of systemic conditions, including can-
cer, renal failure and autoimmune diseases, though in otherwise healthy individuals
the far most common cause of the effusion is a viral pericarditis or perimyocarditis
(Karjalainen & Heikkila 1986, Ammann et al. 1986). CMR can visualize the effu-
sion with a high resolution, thus allowing an accurate quantification of its volume
by planimetry (Ong et al. 2011). Small accumulation of pericardial fluid that is
not circumferential is usually not pathologic. On the other hand, circumferential
effusion (>50ml) that contains non-fluid components (such as fibrinous deposits
or thrombi) is always regarded pathologic (Bogaert & Francone 2009).
1.5.3 Myocardial edema
Edema is an integral part of cellular injury. A mild insult causes only functional
alterations in the permeability of the cellular membrane. This typically leads to
influx of sodium ions, which is followed by an increase in the intracellular water
content - intracellular edema. A more severe insult causes impairment of the
membrane integrity, which leads to leakage of large molecules and efflux of net
water to the extracellular space - extracellular edema. Loss of the large molecules
further aggravates the cellular functions and eventually leads to cellular necrosis.
CMR can visualize the edema by detecting water-bound protons by T2-weighted
imaging (Friedrich et al. 2009). On the T2-weighted images the regions with a
greater water content appear brighter than a surrounding normal tissue. However,
in some patients the edema may be distributed diffusely in the LV myocardium,
thus limiting a comparison of regional differences in the signal intensities within
the myocardium. Therefore the signal intensity of the myocardium is usually
compared with the intensity of a healthy skeletal muscle within the image view.
A ratio of the two respective signal intensities (also called “edema ratio”) of >1.9
indicates myocardial edema (Friedrich et al. 2009).
The ability of CMR to detect myocardial edema has been validated in the set-
ting of acute myocardial infraction and in histologically-verified acute myocarditis
(Friedrich et al. 2009). However, the role of the T2-weighted imaging in the pa-
tients with DCM has not yet been established. In fact, these patients are likely
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to have less pronounced edema than those with acute myocardial infarction or
clinically overt acute myocarditis (Gutberlet et al. 2008).
1.5.4 Hyperemia and capillary leakage
Local vasodilatation along with increased permeability of capillaries for water
and large molecules belong to key pathophysiological processes in tissue inflam-
mation. The increased intravascular and interstitial space can be visualized by
T1-weighted imaging with application of gadolinium contrast. After intravenous
injection the water-soluble contrast agent rapidly distributes to interstitial space.
The increased interstitial space accumulates a greater amount of the contrast than
a healthy tissue. Consequently, the affected myocardial regions appears brighter
on the T1-weighted imaging than healthy myocardium. The dilated capillaries
also contain more of the contrast but these changes are negligible compared to the
volume changes in interstitium. Similarly as in the assessment of edema, the sig-
nal intensity of the myocardial tissue must be related to a healthy skeletal muscle
within the same image. An index of the relative increase in the overall LV signal
intensity is known as early gadolinium enhancement ratio (EGE).
The technique of EGE was validated in induced hyperemia (Miller et al. 1989).
Clinically, it has been used for detection of inflammation of skeletal and also
myocardial muscle (Paajanen et al. 1987, Friedrich et al. 1998, Abdel-Aty et al.
2005).
1.5.5 Myocardial necrosis and replacement fibrosis
Ongoing myocardial necrosis and subsequent fibrotic scarring can be assessed by
the technique of late gadolinium enhancement (LGE). Technical implementation
of the LGE sequence is similar to the EGE, only that the acquisition of the LGE
images begins 10–15 minutes after administration of the contrast Kim et al. (2000).
In a healthy myocardium this time is sufficient for most of the contrast to
diffuse from the interstitial space back to blood, from where it is removed by renal
excretion. However, if the tissue contains excessive interstitial fibrosis (scar) the
large chelates of gadolinium are entrapped in the fibrotic matrix. Although the
contrast is eventually washed-out also from the fibrotic myocardium it may take
up to one hour. Therefore the fibrotic regions remain brighter (enhanced) for
much longer time than a healthy myocardium (see Figure 1).
Under normal conditions the gadolinium chelates cannot enter inside the my-
ocyte. However, if the cellular membrane is being disrupted (for example, by
ischemia or inflammation) the contrast diffuses also in the intracellular space.
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Consequently, the necrotic tissue contains relatively greater amount of the con-
trast and it appears brighter than a surrounding healthy myocardium.
LGE is currently considered a golden standard for in vivo detection of my-
ocardial necrosis (whether ongoing or healed with scar); the technique has been
validated by numerous studies in an animal model and in human. It must be
underlined, however, that LGE cannot discriminate active ongoing necrosis from
a healed fibrotic scar. On the other hand, the pattern and regional distribution of
the LGE can often hint the underlying etiology. In particular, while in the coro-
nary artery disease the LGE follows an ischemic wave-front from the endocardium
towards the epicardium, the LGE of non-ischemic etiology typically presents as
blurry stripes or patches localized anywhere in the LV and it rarely occurs in the
subendocardium (Mahrholdt et al. 2005).
Importantly, the extent of LGE in the LV can be accurately quantified by means
of manual planimetry or by a thresholding technique. Exact quantification of the
LGE is particularly important for serial CMR studies.
Figure 1: Pathophysiological principle of LGE.
After intravenous administration the contrast diffuses to interstitial space. Within
few minutes most of contrast diffuses to the blood to be excreted by kidney (the
left image). In case of an ongoing myocyte necrosis the contrast accumulates also
inside the myocytes. The greater amount of the contrast lead to an increased
(enhanced) signal on T1-weighted imaging (the middle image). In a region with
excessive interstitial fibrosis (i.e., scar) the large chelates of gadolinium remain
entrapped in the fibrous matrix, from where they are wash-out in a much longer
time. Therefore the regions with fibrosis remain brighter for a longer time (the
right image). Adopted from Kim et al. (2000).
15
1.5.6 Increased left ventricular wall stress
Ventricular wall stress depends from the cavity volume, wall thickness and in-
traluminal pressures. Permanent increase in the LV wall stress parallels with the
progression of the heart failure and unfavorable hemodynamic status. In individu-
als with DCM the increased LV wall (verified invasively) has been associated with
presence of LGE (Alter et al. 2007). According to a hypothesis, in the overloaded
LV the myocardium has increased metabolic needs, which in turn leads to rela-
tive ischemia, myocyte necrosis and eventually fibrotic scarring. LGE related to
the hemodynamic stress has been also explained by capillary leakage and delayed
wash-out of the contrast from the affected region. Typically, the LGE has a pat-
tern of a thin mid-wall stripe in the inter-ventricular septum. The predominant
septal and mid-wall localization in the LV suggests that this region is exposed to
the highest mechanical forces.
1.6 CMR for detection of myocardial inflammation
Detection of myocardial inflammation by CMR is based on a complex evaluation
of all the above described tissue parameters. Diagnostic cut-offs for the qunatita-
tive measures have been established and validated against endomyocardial biopsy.
Edema ratio of >1.9 is a sensitive and specific sign of acute myocarditis, though the
finding is uncommon in chronic low-grade inflammation (Gutberlet et al. 2008).
Early postcontrast increase in the LV signal intensity of >45% or EGE >4.0 are
also reliable markers of the acute myocarditis (Friedrich et al. 2009). Presence of
LGE in an otherwise healthy individual with clinically suspected acute myocardi-
tis reliably confirms the diagnosis. However, the sensitivity of LGE depends from
the activity of the inflammation, time from the onset of the disease and associated
LV function. In fact, while LGE has been reported in up to 84% of patients with
acute (days-to-weeks) myocarditis, it was present only in 27–44% patients with
chronic (>6 months) and less-acute (“borderline”) myocarditis (Gutberlet et al.
2008, Friedrich et al. 2009).
1.7 CMR for prediction of the outcome of DCM
Reliable prediction of LVRR and future adverse events has important clinical
implications in an individual with DCM, especially for the cost-effective use of
implantable cardioverter-defibrillators and optimal timing of the referral for heart
transplantation. CMR, by assessment of the myocardial tissue characteristics,
could serve for estimation of the clinical course of the disease. Numerous studies
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have demonstrated strong association between the presence of LGE and a poor
outcome of DCM. However, the prognostic role of LGE was investigated mostly
in the patients with chronic DCM (Bello et al. 2003).
Previously, only one study investigated predictive value of LGE in the specific
population of the patients with new-onset DCM. But the study was undermined
by the fact that the target endpoint was defined by a clinically somewhat irrelevant
5% increase in LV ejection fraction (Leong et al. 2012). Therefore, the prognostic
role of CMR in this subpopulation remains unclear. Of note, while in chronic
DCM the LGE more likely reflects a definite fibrotic scar, in the new-onset DCM
it could account as well for an active (and potentially reversible) myocardial injury.
1.8 Unresolved questions in the area of CMR in DCM
It can be concluded that CMR is reliable in detection of acute myocardial inflam-
mation and somewhat less reliable in chronic myocardial inflammation. However,
the diagnostic performance of CMR has been validated predominately on patients
with clinically overt acute myocarditis who had preserved LV function (Table 2).
Therefore it is not known whether the experience with the diagnosis of myocardial
inflammation by CMR can be fully applied to the setting of DCM.
Table 2: An overview of studies on the use of CMR for detection of myocardial
inflammation.
Publication Year Validation Patients Controls LVdysfunction
Chronic
myocarditis
Friedrich et al. 1998 clinical 19 18 − −
Laissy et al. 2002 clinical 20 7 − −
Rieker et al. 2002 clinical 11 10 − −
Laissy et al. 2005 clinical 24 31 − −
Abdel-Aty et al. 2005 clinical 25 22 − −
Mahrholdt et al. 2006 histological 87 26 − −
Gutberlet et al. 2008 histological 48 35 − +
Yilmaz et al. 2008 histological 55 30 − −
Ong et al. 2011 histological 16 19 − −
Voigt et al.∗ 2011 histological 12 11 + +
Mavrogeni et al. 2011 histological 85 20 − −
Total 402 229
* This was the only work that evaluated performance of CMR for diagnosis of chronic
myocardial inflammation in the setting of DCM. Adopoted from Friedrich et al. (2009).
17
There is only a limited experience with interpretation of the CMR tissue imag-
ing in the patients with new-onset DCM (Leong et al. 2012). In these patients,
similar CMR findings may represent completely different pathophysiological pro-
cesses. For example, LGE may reflect an active and potentially curable myocardi-
tis, a permanent fibrotic scar or as well an ongoing myocardial necrosis related to
the hemodynamic overload (Alter et al. 2007).
In the patients with chronic DCM or ischemic heart disease the finding of LGE
usually remains permanent because it reflects a definite fibrotic scar. In contrast,
in the patients with acute myocarditis and normal LV function the LGE may
recede within several months, after healing of the inflammation (Friedrich et al.
1998). It is not known whether the LGE would recede also in the patients with
new-onset DCM and whether it would be paralleled with LVRR.
At last, there is a sound evidence that in individuals with chronic idiopathic
DCM the presence and extent of LGE projects poor clinical outcome (Bello et al.
2003). In contrast, only one study evaluated predictive value of LGE also in
patients with new-onset DCM (Voigt et al. 2011). No data exists whether the
LGE would also predict adverse clinical events in these patients and whether the
LGE would outperform EMB, biomarkers or other conventional predictors.
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2 Aims and hypotheses
Study aims:
1. To evaluate performance of CMR in detection of myocardial inflammation
in the patients with new-onset DCM, using endomyocardial biopsy as a
reference standard.
2. To clarify pathological and pathophysiological background of the CMR find-
ings in these patients.
3. To evaluate value of the CMR findings for prediction of LVRR and adverse
clinical events in these patients.
Hypotheses:
1. We expect that myocardial inflammation will be a common finding in the
patients with recent-onset DCM.
2. Multisequential CMR imaging could detect the myocardial inflammation
with an acceptable accuracy, provided that the inflammation would have
certain minimal level of activity.
3. Pathophysiology of the CMR findings could be clarified by a simultaneous
assessment by CMR, endomyocardial biopsy and specific cardiac biomarkers.
4. Some CMR findings might reflect myocardial inflammation but they could
also reflect pathophysiological processes related to the heart failure itself.
5. We expect that LVRR would be a common phenomena in our patients. On
the other hand, we expect also a number of severe adverse clinical events.
6. A greater extent of myocardial damage at baseline, as assessed by the LGE
technique, could signify a worse chance for the LVRR and an increased risk
of the adverse clinical events.
7. On the other hand, baseline presence of myocardial edema, assesed by T2-
weighted imaging, and its regression during the follow-up could predict a
better prognosis.
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Rationale for the hypotheses:
Ad 1: Myocardial inflammation can be found in 27-52% of individuals with DCM
(Kawai 1999, Feldman & McNamara 2000). The prevalence of myocarditis
in DCM depends to a great extent on the acuity of the clinical presentation
and on the time of the imaging from the onset of the symptoms. Because the
present study excludes chronic forms of DCM, the prevalence of myocarditis
could be somewhat higher than in an unselected DCM patient population
(Friedrich et al. 1998). On the other hand, it must be pointed out that the
present study also excludes patients with clinically suspected myocarditis.
Ad 2: The diagnostic accuracy of CMR for detection of myocarditis may reach
68-78% in the patients with clinically overt acute myocarditis (Friedrich
et al. 2009). If the inflammation has a low activity, the pathological tissue
processes (such as tissue edema, necrosis and fibrosis) may be smaller than
is the detection capability of CMR (in terms of contrast-to-noise and voxel
resolution) (De Cobelli et al. 2006).
Ad 3: Endomyocardial biopsy will enable to evaluate presence and activity of in-
flammatory cells, myocyte necrosis and extent of interstitial fibrosis (Cooper
et al. 2007). B-type natriuretic peptide, which is synthesized in cardiomy-
ocytes in response to increased wall stress and neurohormal activation, can
be used as a surrogate of LV filling pressures (Schrier & Abraham 1999,
Kazanegra et al. 2001). New-generation (high-sensitivity) cardiac troponin
assays can detect ongoing myocyte necrosis on a submicroscopic level (Sher-
wood & Kristin Newby 2014). Combination of these methods could explain
pathological and pathophysiological background of some of the CMR find-
ings.
Ad 4: In patients with normal LV function, the finding of LGE is a sensitive and
specific sign of myocardial inflammation (Friedrich et al. 1998). However
in the patients with DCM the LGE could also reflect myocardial injury
caused by relative regional ischemia due to hemodynamic overload (Alter
et al. 2007). While the earlier can be detected by EMB the later can be
evaluated by the assessment of cardiac troponins.
Ad 5: Previous studies reported LVRR at 12 months in 27% to 56% of patients
with new-onset DCM, depending on the definition of DCM and on the
therapy of heart failure (Steimle et al. 1994, McNamara et al. 2001, Bink-
ley et al. 2012, Wilcox et al. 2012).The occurrence of LVRR negatively
correlated with adverse clinical events (Merlo et al. 2011).
Ad 6: The LGE reflects active or healed myocardial injury. Studies in various pop-
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ulations with DCM demonstrated association between LGE and a decreased
chance for improvement of LV function and increased risk of adverse clinical
events (Leong et al. 2012, Ismail et al. 2012, Gulati et al. 2013, Zagrosek
et al. 2009)
Ad 7: Initial presence of myocardial edema and its regression during the follow
up may reflect convalescence of initially acute myocarditis (Zagrosek et al.





The study examined consecutive patients with DCM and a history of symptoms
of heart failure shorter than 6 months. DCM was defined by established criteria
as the presence of left ventricular (LV) dilatation (LV end diastolic diameter >33
mm/m in males and >32 mm/m in females) and LV systolic dysfunction (LV
ejection fraction <45%) in the absence of coronary artery disease, severe systemic
arterial hypertension and primary valve disease (Lang et al. 2005, Maron et al.
2006).
Individuals with a history of drug abuse or excessive alcohol consumption, indi-
viduals presenting with persistent supraventricular tachyarrhythmias, individuals
presenting with clinical signs suggestive of acute myocarditis (chest pain accom-
panied by characteristic abnormalities on ECG and significant increase in serum
troponin) and individuals with a contraindication to CMR were excluded.
3.2 Study protocol
Initially, the patients were admitted to a specialized heart failure clinic. All of them
underwent a thorough clinical assessment, ECG, echocardiography, CMR, EMB
and cardiopulmonary exercise testing. Peripheral venous blood was obtained in
the morning before EMB for the measurement of high-sensitivity troponin T (hs-
cTNT), B-type natriuretic peptide (BNP), galectin-3, serum autoantibodies, and
for routine biochemical analysis. EMB was performed within two days following
the CMR. Patients admitted with decompensated heart failure were investigated
only after achieving euvolemic state.
After discharge from hospital, the patients were followed during regular clinical
visits at 3 and 6 months and every 6 months thereafter. The follow-up visits
included clinical assessment, ECG, echocardiography, cardiopulmonary exercise
testing, routine biochemical analysis and measurement of BNP. CMR was repeated
also after 12 months of follow-up in all non-transplanted patients that did not have
an implanted cardiac device. Pharmacotherapy of heart failure was optimized
according to the contemporary guidelines (Dickstein et al. 2008).
Diagnosis of inflammatory DCM was established at baseline, after obtaining re-
sults of the EMB. LVRR was evaluated after 12 months of follow-up. A composite
clinical endpoint of cardiac death, urgent heart transplantation and hospitalization
for worsening of heart failure was recorded during the whole available follow-up.
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3.3 Echocardiography
Echocardiography was performed by experienced operators in accordance with
guidelines of the American Society of echocardiography (Lang et al. 2005, Quinones
et al. 2002). M-mode, 2D images and Doppler recordings were obtained using a
Vivid 7 (GE Healthcare, Chalfont St Giles, UK). LV ejection fraction was as-
sessed using Simpson’s biplane method. Mitral regurgitation was graded semi-
quantitatively on a scale of none, trivial, mild, moderate and severe. Mitral inflow
pattern was classified as restrictive in the presence of an E-wave deceleration time
<120 ms or a ratio of early transmitral flow velocity to atrial flow velocity ≥ 2
associated with an E-wave deceleration time ≤150 ms (Nishimura & Tajik 1997).
LVRR was defined as an absolute increase in LV ejection fraction ≥10% to a final
value of >35%, and at the same time a decrease in LV end diastolic diameter
≥10%.
3.4 Cardiopulmonary exercise testing
Cardiopulmonary exercise testing was performed using a symptom-limited bicycle
ergometry and 25-watt increases in workload every 3 minutes. Minute ventilation,
oxygen consumption, and carbon dioxide output were measured by a heated pneu-
motachograph and mass spectrometry (Sensormedics system, Viasys Healthcare
Inc., Conshohocken, Pennsylvania, USA), as previously described (Kubanek et al.
2006).
3.5 Cardiac magnetic resonance imaging
CMR was performed on a 1.5 Tesla scanner (Avanto, Siemens Medical Solutions,
Erlangen, Germany) equipped with a 12-channel body coil. The entire examina-
tion took about one hour, depending on the patient’s cooperation and heart rate.
Table 3 provides an overview of the used imaging sequences. All the images were
acquired during breath-hold in inspiration.
Cine loops for quantification of cardiac volumes and function were obtained in
standard short-axis and orthogonal long-axis cardiac planes using an ECG-gated
steady-state free precision imaging sequence (True FISP). At least 25 phases were
acquired per heartbeat, thus rendering a typical temporal resolution of 30–40 ms.
T2-weighted images for visualizing myocardial edema were acquired in short-
axis at 1 cm intervals through the left ventricle using a dark blood sequence with
suppression of fat (Fat SAT). The body coil was temporarily deactivated to avoid
hardware-derived signal inhomogeneity.
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Images for assessment of early enhancement were acquired using a T1-weighted
fast low-angle sequence (Turbo FLASH). Three short-axis slices were obtained at
basal, mid-papillary and apical level of the left ventricle. The images were acquired
before and after 40–70 seconds after intravenous bolus injection of 0.2 mmol/kg
of Gadobutrol (Gadovist, Bayer Schering, Germany).
Images for evaluation of late gadolinium enhancement were obtained 10 min
after the administration of the contrast in short-axis and orthogonal long-axis
planes using a 2D phase-sensitive inversion-recovery sequence. A typical scan time
was 7–10 minutes. Triggering of the sequence was set to late systole to minimize
motion-related artifacts. Inversion time was carefully selected on scout images
to null the signal of the presumed normal myocardium. The field of view was
adjusted to maximize spatial resolution. The number of lines in k-space and the
triggering was adjusted according to the patient’s heart rate to minimize motion
artifacts.
Table 3: Typical parameters of the imaging sequences.
Sequence Cine loops T2 EGE LGE
Repetition time (ms) 65 2 x RR 170 690 – 850
Echo time (ms) 1.2 58 1.02 3.2
Inversion time (ms) – 140 100 230 - 300
Flip angle (◦) 70 – 12 –
Field of view (mm) 240 x 260 290 x 380 300x 330 240 x 260
Matrix (pixels) 170 x 190 230 x 300 150 x 165 170 x 190
In-plane resolution (mm) 1.4 x 1.4 1.3 x 1.3 2.0 x 2.0 1.4 x 1.4
Slice thickness (mm) 8 8 10 8
Interslice gap (mm) 0 2 – 0.8
3.6 Analysis of CMR images
Analysis of the CMR scans was blinded to the patients’ clinical data and to the
results of endomyocardial biopsy. Cardiac volumes and function were evaluated
using a dedicated software Segment version 1.8 (Medviso, Lund, Sweden). Myocar-
dial edema index, myocardial EGE ratio and the extent of LGE were quantified
using a custom-made program written in Matlab (Mathworks, Natick, MA, USA).
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3.6.1 Ventricular morphology and function
Ventricular volumes, mass and ejection fractions were measured on the short-axis
cine images. In each slice, the endomyocardial and epicardial contours of both
ventricles were manually delineated at endsystole and enddiastole. Papillary mus-
cles were excluded. Accuracy of the segmentation was simultaneously inspected
on 2- and 4-chamber views (Figure 2). The cardiac phases were defined as the
images containing the smallest and the largest ventricular cross-sectional area,
respectively.
Endsystolic and enddiastolic ventricular cavity volumes were determined by
summation of volumes of the endomyocardial discs. The software enabled to
compensate the endsystolic volume for anterior movement of the mitral annulus.
For this purpose, the distance of the mitral annular movement during systole
was manually measured on a long-axis loop. The measured value was subtracted
from the slice thickness of the most basal slice. Thus, only a fraction of the
volume of the most basal slice was used for the final calculation of the endsystolic
volume. At enddiastole, all the discs were used for the calculation. The volume
of the ventricular myocardium was obtained by subtracting the epicardial and
endocardial discs at enddiastole. The LV mass was derived by multiplying the
myocardial volume by the specific density of myocardium (1.05 g/cm3).
Figure 2: Evaluation of cardiac volumes and function by CMR
The figure demonstrates quantification of ventricular volumes and function in a
patient with DCM. Contours of both ventricles were manually traced on each of
the short-axis images (left panels) during enddiastole (top row) and endsystole
(bottom row). Accurracy of the segmentation was veryfied on the long-axis views
(middle and right panels).
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3.6.2 Myocardial edema
Myocardial edema was evaluated on the T2-weighted short-axis images according
to a previously described method (Friedrich et al. 2009). At first, 3–4 slices con-
taining a cross-section through a paraspinal or a pectoral muscle were selected.
The skeletal muscles were identified by side-by-side viewing of the T2-weighted
images and the T1-weighted cine images. The left ventricular myocardium was
manually delineated. Another region of interest with an area of 2–3 cm2 was man-
ually drawn over the skeletal muscle (Figure 3). For each slice, the myocardial
edema index was calculated by dividing the mean signal intensity of the left ven-
tricular myocardium by the mean signal intensity of the reference skeletal muscle.
Global myocardial edema index was obtained by averaging the values from each
of the slices. A higher value of the index reflected a greater myocardial water
content. A value of ≥1.9 was regarded as abnormal (Friedrich et al. 2009).
Figure 3: Evaluation of myocardial edema by CMR
The figure demonstrates quantitative assesment of global left ventricular myocar-
dial edema on a T2-weighted image. Myocardial edema index was calculated by
dividing the mean signal of the left ventricular myocardium by the mean signal
of a region of a refernce skeletal muscle in the view. Tissue containing a greater
water content appeared brighter.
3.6.3 Pericardial effusion
Pericardial effusion was quantified by summation of volumes of manually delin-
eated regions on the T1-weighted short-axis images. T2-weighted images were
simultaneously reviewed to differentiate the effusion from epicardial fat. A total
effusion volume of >50 ml was regarded pathological (Bogaert & Francone 2009).
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3.6.4 Early gadolinium enhancement
Myocardial early enhancement was quantified on the Turbo FLASH images ac-
cording to the method by Laissy et al. (2005). Similarly as for the myocardial
edema index, the left ventricular myocardium and a skeletal muscle in the view
were manually segmented on the pre- and postcontrast images (Figure 4). My-
ocardial relative enhancement was calculated by the formula: mean postcontrast
signal – mean precontrast signal / mean precontrast signal. The same formula
was applied for calculating relative enhancement of the reference skeletal muscle.
The myocardial early enhancement ratio was obtained by dividing the relative
myocardial enhancement by the relative skeletal muscle enhancement. Value from
all the three slices were averaged to obtain the myocardial global early gadolinium
enhancement ratio (EGE). A value of ≥45% was regarded abnormal (Laissy et al.
2002).
Figure 4: Assessment of myocardial early gadolinium enhancement ratio
The figure demonstrates quantification of EGE ratio. Left ventricular myocardium
and a reference skeletal muscle in the view were manually delineated on a precon-
trast and a postcontrast image. The mean singal intestities of the segmented
regions were used for the calculation of the relative enhancement.
3.6.5 Late gadolinium enhancement
The presence of late gadolinium enhancement (LGE) and its localization in the
left ventricle were independently determined by two expert radiologists. The LGE
had to be visible in phase-sensitive and also in magnitude-reconstructed sequences.
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Any LGE finding in the short-axis view had to be confirmed in an orthogonal long
axis view through the lesion.
The extent of LGE in the left ventricle was quantified on the short-axis images
by a semiautomatic algorithm adopted from Heiberg et al. (2005). The left ven-
tricular myocardium was segmented manually. In each slice the program automat-
ically delineated a region in the left ventricular wall that contained an intersection
of a 15 degree sector of the wall and the central 80% of the wall thickness. Mean
signal intensity of the region was recorded. This process was repeated iteratively
by one degree steps until the whole left ventricular wall was encircled. The region
with the lowest mean signal intensity was set as a reference tissue. Myocardial tis-
sue with signal intensity >2 standard deviations above the mean of the reference
myocardium was regarded as abnormally enhanced (Kim et al. 1999). Isolated
regions of LGE that were smaller than 1.5 ml were regarded as artefacts and they
were automatically removed. The extent of LGE was expressed as a weight of tis-
sue and also as a percentage of left ventricular mass (indexed LGE extent). Figure
5 demonstrates the process of the quantification of the extent of LGE. Another
example is shown on the Figure 12 (page 50).
Figure 5: Quantification of the extent of LGE
The figure shows a custom-made program for semiautomatic quantification of the
extent of LGE in the left ventricle. The LGE is quantified slice-by-slice and
summed for the whole ventricle. The program automatically identifies a region
of a predefined size with the lowest signal intensity (depicted by pink color on the
figure). This region is classified as a reference “healthy” myocardium. The LGE
is outlined automatically by applying a threshold of 2 standard deviations above
the mean signal intensity of the reference myocardium (depicted by yellow color).
Artifacts can be removed by adjusting a minimum LGE weight (in grams) or min-
imum LGE area (in pixels). To improve homogeneity of the image, the program
allows also median image filtering with an adjustable size of the kernel.
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3.7 Assessment of cardiac biomarkers
Plasma levels of BNP were measured immediately after blood sampling using
a commercially available electrochemiluminescent immunoassay (Architect BNP,
Abbott Diagnostics, Illinois, U.S.A.). The lower limit of detection was 10ng/L;
intra- and inter-assay coefficient of variation (CV) was 3.8% and 5.3%. Serum
for assessment of hs-cTnT was frozen at −30◦C until batch analysis. Hs-TnT was
measured by an electrochemiluminescent immunoassay (T-hs-STAT, Cobas e411,
Roche Diagnostics GmbH, Mannheim, Germany). The lower limit of detection
was 5ng/L; CV at 13 ng/L was 10%, intra- and inter-assay CV was 3.2% and
6.2%. The upper reference limit was set at 13.5ng/L. Glomerular filtration rate
was estimated using the Modification of Diet in Renal Disease (MDRD) formula
(Levey et al. 1999).
3.8 Endomyocardial biopsy
Endomyocardial biopsy was performed under fluoroscopic guidance via the right
internal jugular vein using a flexible bioptome (diameter 7F, Cordis Europe,
Netherlands). Myocardial specimens were harvested from the right ventricular
side of the interventricular septum. There were no complications related to the
procedure.
At least four samples were fixed in 4% buffered formaldehyde for histopatholog-
ical and immunohistochemical analysis. Another three samples were placed under
aseptic conditions into ice-cold sterile saline and immediately transferred into the
microbiological laboratory for detection of viral genome.
3.8.1 Histopathological analysis
Light microscopy was performed on 4-µm-thick sections from paraffin-embedded
endomyocardial biopsy specimens stained with hematoxylin-eosin, periodic acid-
Schiff, elastic picro-sirius red and Masson’s trichrome. Histopathological analysis
followed the Dallas criteria (Aretz et al. 1987). Active myocarditis was defined
by the finding lymphocytic infiltrates associated with myocyte necrosis. Finding
of inflammatory infiltrates but without signs of myocyte injury was classified as
borderline myocarditis.
The extent of interstitial fibrosis was evaluated on the picrosirius-stained slides
by a morphometric study as described by Loud & Anversa (1984). At least three
representative microscopic fields (enlargement of 400 x) were analyzed in each
biopsy specimen. Each microscopic field was superimposed by a grid of 100 in-
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tersection points. The points overlying red-colored (fibrotic) tissue were counted.
To calculate the percentage of interstitial fibrosis, the sum of the counted fibrotic
points from all the fields were divided by the total number of points in the fields.
Areas containing artifacts or perivascular fibrosis were excluded from the calcula-
tion.
Myocyte vacuolization (a sign of the myocyte degeneration) was graded on a
semiquantitative scale: 1 = no or scarce vacuolization, 2 = focal vacuolization, 3
= extensive vacuolization.
3.8.2 Immunohistochemical analysis
CD3 and CD68 and positive cells were detected on 4 µm-thick paraffin sections
of the biopsy samples using a two-step indirect method. The slides were deparaf-
finized in xylene, rehydrated in graded ethanol and heated in 0.01M citrate buffer
pH 6.0 (detection of CD68) and EDTA buffer pH 8,0 (detection of CD3) for target
retrieval. Endogenous peroxidase was blocked by 0.3% H2O2 in 70% methanol
for 30 minutes. The primary antibodies (both from Dako, Glostrup, Denmark)
were applied for 30 minutes. They were detected by polymer Histofine Simple
Stain MAX PO (Nichirei, Japan). Finally, the specimens were covered for 5 min-
utes with Dako Liquid DAB+ Substrate-Chromogen System (Dako, Glostrup,
Denmark), counterstained with Harris’s hematoxylin (Merck, Germany) and em-
bedded in Entellan (Merck, Germany).
Immunohistochemical criteria of myocardial inflammation were based on detec-
tion of mononuclear infiltrates: either >7 per mm2 of CD3 postitive T-lymphocytes
or a combination of >14 per mm2 of CD3 positive T-lymphocytes or CD68 positive
macrophages (Richardson et al. 1996).
3.8.3 Detection of viruses in the myocardium
Isolates from the EMB specimens were used to detect the following viruses: human
cytomegalovirus, Epstein- Barr virus, human herpes virus 6, parvovirus B19, ade-
noviruses and enteroviruses (including coxackieviruses and echoviruses). Nucleic
acids were isolated with QIAamp DNAMini Kit (Qiagen Gmbh, Hilden, Germany)
and RTP DNA/RNA Virus Mini Kit (Invitec, Berlin, Germany) according to the
protocol for purification of nucleic acids from tissues. Cytomegalovirus was de-
tected by an in-house assay as reported previously (Pumannova et al. 2006). The
remaining viruses were analyzed using commercially available assays: LightMix
EBV Kit and LightMix HHV-6 Kit (both from TIB MOLBIOL Gmbh, Germany),
LightCycler Parvovirus B19 Quantification Kit (Roche Diagnostics, USA), Aden-
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ovirus R-Gene Kit (Argene, Verniolle, France) and Enterovirus R-Gene Real-Time
Kit (Argene, Verniolle, France).
3.9 Ethics
The investigation conformed to the principles outlined in the Declaration of Helsinki
(WMA 2004). It was approved by the institutional ethics committee. All subjects
signed an informed consent prior to their participation in the study.
3.10 Statistical analysis and data reporting
All statistical analyzes were conducted with SPSS version 17.0 (SPSS, Chicago,
IL). P <0.05 was considered to be statistically significant.
Values are reported as frequency (percentage), mean ± standard deviation or
median [interquartile range].
Categorical variables were compared using the chi-square or Fisher’s exact test.
Continuous variables were compared by the Student’s t-tests or by the Mann-
Whitney U test, as appropriate. Because of right-skewed distribution, the concen-
trations of BNP and hs-TnT were log-transformed before analysis.
To identify independent factors associated with myocardial inflammation, LVRR
and presence of LGE, variables that significantly differed in the univariate between-
group analyzes were entered into a multiple stepwise logistic regression analysis.
Predictive performance of the selected variables was assessed using receiver oper-
ator characteristics (ROC) analysis. Log-rank test and Cox’s proportional hazard
model, using the time to first event, were performed to analyze associations be-





A total of 44 Caucasians with new-onset DCM were investigated. Two of the pa-
tients were excluded from the head-to-head comparison of CMR and EMB because
of poor image quality of the EGE sequence. For the evaluation of LVRR, all the
44 patients had complete clinical, laboratory, echocardiography and biopsy data,
along with CMR-derived ventricular volumes and function, LGE sequences and
T2-weighted sequences. Baseline clinical characteristic of the study population
are summarized in Table 4.
4.2 Clinical characteristics of patients with new-onset DCM
A typical patient with new-onset DCM was a middle-aged man without a previous
medical history. None of the patients had a history of coronary artery disease, pe-
ripheral arterial disease or stroke. Only two individuals were treated for diabetes
mellitus, but in both cases it was adequately controlled only by oral antidiabetics.
Three patients were treated for arterial hypertension; they had normal blood pres-
sure on medication. All but one patient had initially sinus rhythm. One patient
presented with persistent atrial fibrillation but she did not have an excessive heart
rate. After performing electric cardioversion he remained in sinus rhythm for the
rest of the follow-up.
Importantly, none of the patients presented with a clinical picture that would
suggest an acute myocarditis (chest pain, marked elevation of cardiac troponin,
characteristic abnormalities on electrocardiography or an audible pericardial fric-
tion rub). In contrast, about every forth patient reported typical symptoms of a
viral respiratory disease occurring a few weeks before onset of the symptoms of
heart failure. Also, interestingly, every fourth patient reported a family history of
a cardiomyopathy in at least one of his first-degree relatives.
Before the baseline evaluation, the patients had been suffering from symptoms
of heart failure for median 2 months (minimum 2 weeks, maximum 6 months). The
most typical complaints included exertional dyspnea, markedly lowered tolerance
of physical activity or ankle swelling. At the time of their first medical contact
two thirds of the patients had to be hospitalized for decompensated heart failure.
Initially, the patients were usually treated at a regional community hospital
before they were referred to our center for further investigation and treatment.
At the time of admission to our center 68% were hemodynamically stable, 18%
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Table 4: Baseline characteristics of the study population.
Variable n = 44
Clinical variables
Age (years) 43± 11
Males 31 (71%)
Family history of dilated cardiomyopathy 11 (25%)
Diabetes mellitus 2 (4%)
Systemic hypertension 3 (7%)
Viral prodromes during preceeding month 12 (27%)
Duration of symptoms of heart failure (months) 2.0 [1.0–3.4]
Hospitalisation for heart failure in previous 6 months 29 (66%)






Body mass index (kg/m2) 25± 4
Systolic blood pressure (mmHg) 112± 17
Diastolic blood pressure (mmHg) 69± 7
Heart rate (beats/min) 84± 18
Sinus rhythm 43 (98%)
QRS duration (ms) 106± 21
Complete left bundle branch block 5 (11%)
Exercise capacity∗
Peak exercise heart rate (beats/min) 142± 17
Peak exercise systolic BP (mm Hg) 135± 22
Peak oxygen consumption (ml kg/min) 19.4± 0.5
Peak oxygen consumption (% of predicted value) 57± 16
VE/VCO2 slope 28.8± 0.9
Biomarker testing
Sodium (mmol/l) 141± 2
Creatinine (µmol/l) 95± 4
Estimated glomerular filtration rate (ml/min) 79± 23
B-type natriuretic peptide (ng/l) 635 [276–1081]
High-sensitivity troponin T (ng/l) 14.5 (5.0–30.0)
High-sensitivity troponin T positive† 23 (52%)
Conventional troponin I positive† 13 (29%)
Galectin-3 (µg/l) 3.0 [0.2–4.6]
C-reactive protein (mg/l) 3.0 [1.0–8.2]
* Available in 41 patients; † Troponin positivity was defined as high-sensitivity troponin
T >13.5 ng/l or conventional troponin I >0.03 µg/l.
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had decompensated heart failure that did not require treatment with inotropes and
another 14% had decompensated heart failure requiring treatment with inotropes.
The patients presented mostly with NYHA II functional class (52%), followed by
NYHA III (32%), NYHA IV (14%) and NYHA I functional class (2%). Table 5
shows an overview of the patients’ medication at the time of the CMR during the
index hospitalization.
After admission to our center, the patients with decompensated heart failure
were first managed by diuretics and, if necessary, by inotropes to achieve an euv-
olemic state. This phase usually took 1-2 weeks. CMR, EMB and blood sampling
for assessment of cardiac biomarkers was performed (if possible) only after the
initial compensation. Functional exercise testing was performed only in hemody-
namically stable individuals before a planned discharge to home.
Table 5: Baseline pharmacotherapy of heart failure.
Medication class n = 44
ACEI/ARB 40 (91%)
ACEI or ARB ≥ 50% of maxinum recommended dose 10 (23%)
Beta-blockers 41 (93%)
Beta-blockers ≥ 50% of maximum recommended dose 11 (25%)
Furosemide 40 (91%)
Furosemide ≥ 40mg/day 30 (68%)
Spironolactone 35 (80%)
Intravenous furosemide or spironolactone 13 (29%)
Inotropes∗ 6 (14%)
* The inotropes consisted of low dose of dobutamine in five patients and dopamine in
an another patient.
4.3 Baseline cardiac function
Key parameters of the patients’ baseline cardiac function, as assessed by echocar-
diography and CMR, are summarized in Table 6. As a rule, the patients had
dilated left ventricle (LV) with severely impaired systolic function. The mean LV
fraction was 21 ± 10% by echocardiography and 23 ± 7% by CMR (range, 8–
41%). The average volume of the LV was 280 ± 85 ml, ranging from 117 ml up
to 548 ml; mean LV enddiastolic diameter was 67 ± 7 mm (range, 48–83 mm).
LV systolic dysfunction was often paralleled by systolic dysfunction of the right
ventricle.
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Importantly, as much as 39% of the patients had also severely impaired left
ventricular diastolic filling, which was reflected by a restrictive pattern of LV filling
on Doppler echocardiography. Furthermore, more than a half of the patients had
at least moderate functional mitral regurgitation, which was usually accompanied
by dilated left atrium and signs of pulmonary hypertension.
Baseline exercise testing was performed in 41 (93%) of the patients. Three
patients were unable to perform the exercise testing because they remained hemo-
dynamically unstable. As expected, the patients with recent-onset DCM showed
markedly reduced exercise tolerance: VO2 max was 57 ± 16% of the expected
values in healthy population matched for age and gender.
Table 6: Baseline assessment of cardiac morphology and function.
Variable n = 44
Echocardiography
LV enddiastolic diameter (mm) 69± 6
LV enddiatstolic diameter index (mm/m) 39± 3
Interventricular septum thickness (mm) 9± 1
Posterior wall thickness (mm) 8± 1
LV ejection fraction (%) 23± 7
Restrictive pattern of mitral inflow 17 (39%)
E/E’ ratio 13.2± 0.5
Left atrial short axis diameter index (mm/m) 26± 4
Left atrial volume index (ml/m2) 49± 19
Mitral regurgitation mdrate or severe 25 (57%)
RV enddiastolic diameter (mm) 29± 6
TAPSE (mm) 17± 5
Magnetic resonance imaging
LV enddiastolic volume (ml) 280± 85
LV enddiastolic volume index (ml/m2) 140± 40
LV ejection fraction (%) 21± 10
LV ejection fraction category





LV mass (g/m2) 105± 26
RV enddiastolic volume index (mL/m2) 77± 30
RV ejection fraction (%) 24± 8
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4.4 Findings in endomyocardial biopsy
The findings in the endomyocardial biopsy are summarized in Table 7. Figure 7
shows several representative images from the histological and immunohistochem-
ical analysis. Immunohistochemical analysis of the endomyocardial biopsy spec-
imens revealed myocardial inflammation in 15 individuals. The classical Dallas
(histological) criteria of myocarditis were met only in three of the cases, but even
in these three individuals the inflammation was classified as borderline.
In summary, 34% patients had inflammatory DCM. Of them 7% had border-
line myocarditis according to Dallas criteria and 27% had low-activity myocardial
inflammation detected only by immunohistochemistry (but not by histopathol-
ogy). The remaining 66% of patients were concluded to have an idiopathic DCM
(Figure 6).
Figure 6: Diagnoses based on the endomyocardial biopsy findings
In the patients with myocarditis, the mean count of CD3+ T lymphocytes and
CD68+ macrophages was 12 ± 5 and 8 ± 4 per mm2, respectively. Two thirds
of the patients had present at least one virus genome in the biopsy specimens.
The most common genome found was parvovirus B19, followed by human cy-
tomegalovirus and one case of enterovirus (Table 7). Human herpes virus 6 and
adenoviruses were not found in any of samples.
Some degree of myocardial interstitial fibrosis was present in all the patients.
The mean extent of fibrosis was 15 ± 5%. There was no difference in the extent
of myocardial fibrosis with respect to the presence of myocardial inflammation.
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Figure 7: Typical findings in histological and immunohistochemical analysis
Panel A: Hematoxylin-eosin (HE) staining, zoom 200x. The image shows an acute
myocarditis with diffuse lymphocytic infiltrate and focal necrosis of myocytes.
This specimen was obtained in a patient with fulminant myocarditis who was not
involved in this study.
Panel B: HE staining, zoom 200x. The image shows a borderline myocarditis
with a more subtle lymphocytic infiltrate but no signs of myocytic degeneration
or necrosis.
Panel C: HE staining, zoom 10x. The image shows borderline myocarditis with
lymphocytic infiltration, which is accompanied by extensive interstitial replace-
ment fibrosis.
Paned D: Immunohistochemical analysis with antibodies targeting CD3 antigens,
zoom 10x. The image illustrates findings in individuals with a positive immuno-
histochemistry detecting inflammation. The brown dots represent CD3 positive
T-lymphocytes.
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Table 7: Findings in the endomyocardial biopsy.
Variable n = 44
Area of available biopsy specimen (mm2) 6± 2
Myocardial inflammation∗ 15 (34%)
Myocardial inflammation by immunohistochemistry† 12 (27%)
Borderline myocarditis by histological criteria‡ 3 (7%)
CD3+ T lymphocytes (n/mm2) 4 [2–9]
CD68+ macrophages (n/mm2) 2 [0–5]
Presence of virus genome 29 (66%)
Parvovirus B19 positive 27 (61%)
Parvovirus B19 in EMB (copies/µgof DNA) 120 [0–622]
Human cytomegalovirus 4 (9%)
Enterovirus 1 (2%)
Human herpes virus 6 0 (0%)
Adenoviruses 0 (0%)
Extent of myocardial fibrosis (%) 15± 5
Degree of myocyte vacuolization (grades 1–3)§ 2 [2–3]
∗ Presence of > 7 /mm2 of CD3+ T-lymphocytes or a combination of > 14 /mm2 of
CD3+ T-lymphocytes or CD68+ macrophages. † Immunohistochemical proof of my-
ocardial inflammation but no signs of myocyte necrosis on histopathological assessment.
‡ Immunohistochemical and histopathological signs of myocardial inflammation with
associated myocyte necrosis. § Grade 1 signifies absent or scarce vacuolization; grade
2, focal vacuolization and grade 3, extensive vacuolization or apoptosis.
4.5 Feasibility of CMR for assessing myocardial tissue
characteristics
The image quality was good or acceptable in all but two individuals, in whom
the scans were uninterpretable for evaluation of EGE ratio. In one case, the poor
image quality was caused by heart motion artifacts; in the other case it resulted
from an inappropriately selected inversion time. The sequences for evaluation of
LGE and the myocardial edema ratio were interpretable in all cases.
There was a good agreement on the presence of LGE between the two raters
(Kappa = 0.75, 95% CI [0.53, 0.97], P = 0.001). Also, there was an excellent
inter-observer reproducibility of the measurements of the quantitative parameters
(extent of LGE, myocardial edema ratio and early enhancement). The relative
variability of the measurement at a repeated analysis after three months was for
extent LGE, 5.2 ± 4.5%; for myocardial edema ratio, 6.9 ± 6.8%; and for early
myocardial enhancement, 10.1 ± 7.3%. The biases and the limits of agreement
for the repeated measurements of the quantitative tissue parameters are shown in
the Blant-Altman plot on the Figure 8.
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Figure 8: Reproducibility of the CMR quantitative tissue parameters
The red dotted lines represent the bias and limits of agreement at the 95 % confi-
dence interval.
4.6 Accuracy of CMR for detection of myocardial
inflammation
Tables 8 and 9 present comparison of clinical and CMR variables between patients
with and without myocardial inflammation. A receiver-operator curve analysis
of the diagnostic performance of the quantitative CMR parameters (myocardial
edema ratio, EGE ratio and extent of LGE) for detection of myocardial inflam-
mation is presented in Figure 9. The overall diagnostic performance of CMR for
detection of myocardial inflammation is presented in Table 10.
The groups did not differ in the volume, mass or systolic function of the ven-
tricles. Also, the two groups did not differ in the myocardial edema ratio. Conse-
quently, the edema ratio proved insufficient for detection of myocarditis in DCM.
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EGE was significantly increased in the patients with inflammatory DCM com-
pared the idiopathic DCM. The parameter retained its independent predictive
value also in a multivariate logistic regression analysis (Table 10). However, a
receiver-operating characteristic analysis revealed only a modest diagnostic per-
formance of this CMR sign (Figure 9). Moreover, the finding of an abnormally
increased EGE ratio above the arbitrary cut-off of 45% was rather uncommon in
our study population (it was present only in 6 cases of inflammatory DCM and in
1 case of idiopathic DCM). Thus, while this CMR sing was highly specific it had
a low sensitivity for detection of myocardial inflammation.
Table 8: Comparison of clinical, laboratory and biopsy data between individuals






n = 27 n = 15
Age (years) 45± 12 42± 8 0.29
Males 19 (70%) 11 (73%) 0.81
Duration of heart failure (months) 2 [1–3] 2 [1–3] 0.58
Prodromes of viral disease∗ 5 (19%) 6 (40%) 0.13
NYHA class 2.4± 0.9 2.8± 0.8 0.23
Diabetes mellitus 1 (4%) 1 (7%) 0.66
Systemic hypertension 2 (7%) 1 (7%) 0.93
GFR (ml/min/m2) 81± 23 79± 15 0.69
ACEI/ARB 24 (89%) 14 (93%) 0.64
Beta-blockers 5 (19%) 4 (27%) 0.54
Furosemide 24 (89%) 14 (93%) 0.66
Spironolactone 20 (74%) 13 (87%) 0.34
Normal sinus rhytm 26 (96%) 15 (100%) 0.45
Left bundle-branch block 3 (11%) 2 (13%) 0.83
Hs-TnT (ngL) 11 [5–32] 17 [5–30] 0.55
Hs-TnT positive† 12 (44%) 10 (67%) 0.20
Troponin I maximum (µg/L) 1.6 1.7 —
Conventional troponin I positive† 7 (26%) 6 (40%) 0.34
C-reactive protein (mg/L) 2 [1–7] 3 [2–9] 0.36
B-type natriuretic peptide (ng/L) 963 [240–1508] 647 [279–1180] 0.27
Viral genome in biopsy 16 (59%) 11 (73%) 0.36
Extent of fibrosis in biopsy (%) 14± 7 15± 9 0.61
* Prodromes of a viral disease during the preceding month before onset of the symptoms
of heart failure. † Hs-TnT >13.5 ng/l or conventional troponin I >0.03 µg/l.
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n = 27 n = 15
LV enddiastolic diameter (mm) 67 ± 8 71 ± 7 0.14
LV mass (g/m2) 106 ± 26 106 ± 27 0.96
RV ejection fraction (%) 24 ± 9 23 ± 8 0.64
RV enddiastolic volume (ml/m2) 80 ± 35 76 ± 23 0.71
Interventricular septum (mm) 9 ± 2 9 ± 2 0.45
Edema ratio 1.5 ± 0.3 1.5 ± 0.4 0.67
Edema ratio > 1.9 2 (7%) 2 (13%) 0.63
EGE present 22 ± 13 38 ± 32 0.030∗
EGE > 45% 1 (4%) 6 (40%) 0.005∗
LGE present 15 (56%) 13 (87%) 0.049∗
Extent of LGE† (% of LV mass) 6 ± 4 5 ± 3 0.625
LGE mid-wall stripe pattern 11 (41%) 9 (60%) 0.23
Pericardial effusion > 50ml 3 (11%) 7 (47%) 0.020∗
* The symbol highlights a p-value <0.05. † Only in those with present LGE.
Table 10: Performance of CMR in detection of myocardial inflammation in DCM
Variable Sensitivity Specificity Accuracy OR [95% CI]
Myocardial edema∗ 13% 93% 64% NS
Increased EGE† 40% 96% 76% 17 [2–164]
LGE present 87% 44% 60% 5 [1–28]
Pericardial effusion‡ 47% 89% 74% 7 [1.5–34]
Any two criteria simultaneously 67% 85% 79% 12 [3–52]
LGE + increased EGE 86% 74% 76% 17 [2–164]
LGE + pericardial effusion 70% 75% 74% 7 [1.5–37]
NS signifies statistically not significant by logistic regression. OR = odds ratio; CI =
confidence interval; * Edema ratio >1.9; † EGE > 45%; ‡ Pericardial effusion > 50ml
41
Figure 9: Performance of the individual quantitative CMR tissue parame-
ters in the detection of myocardial inflammation
The figure shows a ROC analysis of three quantitative CMR tissue parameters
for detecting myocardial inflammation in new-onset DCM. The myocardial edema
ratio performed poorly (left plot). Early enhancement ratio showed only a modest
diagnostic performance (middle plot). Quantification of the extent of LGE (right
plot) did not add any diagnostic value compared to a simple binary statement of
the presence LGE.
Similarly, an abnormal pericardial effusion (>50 ml) was quite uncommon in
the patients with new-onset DCM but it was more frequent in inflammatory com-
pared with idiopathic DCM. In a multivariate regression analysis, the finding of
an abnormal pericardial effusion was an independent predictor of myocardial in-
flammation (Table 10). Of note, the effusion did not cause any hemodynamic
compromise to the patients because it was never of a large volume (mean volume,
76 ml, range 52–185 ml).
LGE was present in 67% of the study group. It was significantly more prevalent
in the patients with inflammatory DCM. In the multivariate regression analysis,
the finding of LGE was an independent predictor the myocardial inflammation
(Table 10). Quantification of the extent of LGE did not improve the diagnosis
compared to a simple binary classification of its occurrence in the LV (Figure 9).
The LGE had a pattern of a single, thin, mid-wall stripe located in the in-
terventricular septum (n = 12) or within inferolateral or lateral wall (n = 4),
multiple mid-wall stripes located in different areas (n = 7) or a patchy transmural
lesion found predominantly in lateral wall (n = 5, Figure 10). We did not observe
any characteristic pattern or a typical localization of the LGE that would reliably
identify the individuals with myocardial inflammation (interventricular septum
[Figure 10 A–B] vs. nonseptal regions [Figure 10 C–D]; 16 of 28 [50%] vs. 12
of 28 [42%], respectively; P = 0.66). Moreover, no characteristic localizations or
patterns of LGE were observed with regard to a particular viral genome.
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In summary, the diagnostic performance of CMR was suboptimal for clinical
application. LGE was sensitive but not specific for myocardial inflammation, while
abnormal pericardial effusion and increased EGE ratio turned to be specific but
less sensitive findings. In fact, the most accurate diagnostic approach was achieved
if the CMR criteria for myocardial inflammation was defined as the simultaneous
presence of any two of the above three CMR signs.
Figure 10: Examples of LGE in the patients with new-onset DCM
The figure illustrates various typical patterns of LGE which can be found in indi-
viduals with new-onset DCM.
Panels A and B: a thin mid-wall stripe located in the interventricular septum.
Panel C: multiple patches of LGE located in the LV septum and also in the LV
free wall.
Panel D: extensive transmural LGE in the LV free wall.
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4.7 Pathophysiology of LGE
Table 11 shows univariate analysis of the variables related to LGE. The presence
of LGE was significantly associated with the finding of myocardial inflammation in
biopsy (as detected by immunohistochemistry), with an ongoing myocyte necro-
sis (represented by increased hs-cTnT concentrations) and with a more advanced
heart failure (as reflected by higher NYHA functional class and higher BNP con-
centrations).
In multivariate regression analysis only the biopsy finding of myocardial inflam-
mation and BNP concentrations remained independent predictors of LGE (odds
ratio [95% CI] = 11.0 [1.3 - 96] and 3.5 [1.3 – 9.8] per ln ng/L; P = 0.03 and
0.017, respectively). BNP and NYHA class were included into the models sepa-
rately because of a significant mutual correlation. In addition, the relative extent
of LGE correlated with the hs-cTnT and BNP concentrations (r = 0.68 and 0.53,
respectively; P < 0.001).
Interestingly, the extent of fibrosis evaluated in the biopsy specimens did not
differ between the patients with and without LGE.
Table 11: Variables associated with occurrence of LGE in the left ventricle.
Variable LGE absentn = 14
LGE present
n = 28 p Value
NYHA class 2.2 ± 0.7 3.0 ± 0.8 0.006∗
LV ejection fraction (%) 23 ± 11 21 ± 9 0.44
LV enddiastolic volume (ml/m2) 128 ± 38 147 ± 42 0.19
LV enddiastolic diameter (mm) 67 ± 9 69 ± 7 0.47
LV mass (g/m2) 108 ± 28 123 ± 23 0.59
B-type natriuretic peptide (ng/L) 283 [113–812] 1031 [592–1469] 0.003∗
Hs-TnT (ng/L) 6 [4–16] 18 [9–54] 0.021∗
Hs-TnT > 13.5 ng/L 4 (28%) 19 (68%) 0.02∗
Troponin I > 0.03 µg/L 3 (21%) 10 (36%) 0.35
Troponin I maximum (µg/L) 0.3 3.6 —
GFR (ml/min/m2) 74 ± 24 82 ± 18 0.40
Inflammation in EMB 2 (14%) 13 (46%) 0.04∗
Fibrosis extent in EMB (%) 12 ± 5 16 ± 9 0.18
* The symbol highlights a p-value <0.05.
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Figure 11: Variables associated with presence of LGE in new-onset DCM
4.8 Occurrence of LVRR and its relation to clinical,
exercise, echocardiographic and laboratory variables
A complete follow-up for evaluation of LVRR was available in 39 patients (89%)
that did not receive a heart transplant or a ventricular assist device. At 12 months,
LVRR was observed in 20 individuals (45%). But only 3 of the patients (7%)
improved LV ejection fraction above 50 %.
Tables 12–14 present comparison of variables recorded at baseline and at 3, 6
and 12 months with regard to LVRR at 12 months. Already after three months
the patients with future LVRR had significantly smaller indexed LV enddiastolic
diameter, improved LV diastolic function, decreased BNP, less frequent moderate
or severe mitral regurgitation, smaller left atrial diameter and left atrial volume,
lower resting heart rate, improved NYHA functional class and also improved all
measures of functional exercise testing. Of note, at three months the LV and the
RV ejection fraction did not yet differ from the patients without LVRR.
After 6 months, the patients with future LVRR differed even more significantly
in the indexed LV enddiastolic diameter, LV diastolic function, levels of BNP,
prevalence of mitral regurgitation and in the left atrial diameter and volume. In
addition, at 6 months the patients with future LVRR had already significantly
higher LV ejection fraction (but not RV ejection fraction) and smaller absolute
LV enddiastolic diameter. After one year, the LVRR was accompanied—besides
the default improvement of LV function and dimensions—by markedly improved
functional capacity, absence of moderate or severe mitral regurgitation, a shorter
QRS complex duration, lower BNP levels and also by improvement of RV ejection
fraction (but not RV enddiastolic volume), as assed by CMR.
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Table 12: Comparison of baseline variables with regard to LVRR—part I
Variable
Baseline data Data at 1 year
LVRR− LVRR+ LVRR− LVRR+
n = 24 n = 20 n = 19 n = 20
Clinical variables
Age 42± 14 45± 8 − −
Males 16 (66%) 15 (75%) − −
Familiy history of DCM 8 (33%) 3 (15%) − −
Diabetes mellitus 1 (2%) 1 (2%) − −
Systemic hypertension 1 (4%) 2 (10%) − −
Viral prodroms 6 (25%) 6 (30%) − −
Duration of HF (months) 1.6 [1.0–4.0] 2.0 [1.0–3.0] − −
Decompensated HF 11 (46%) 3 (15%)∗ − −
NYHA I 1 (4%) 0 2 (11%) 14 (70%)∗∗∗
II 9 (37%) 14 (70%) 12 (63%) 6 (30%)
III 10 (42%) 4 (20%) 5 (26%) 0
IV 4 (17%) 2 (10%) 0 0
BMI (kg/m2) 25± 4 25± 3 27± 5 26± 4
Systolic BP (mm Hg) 111± 14 114± 20 112± 12 114± 17
Heart rate at rest (bpm) 85± 19 83± 19 73± 13 67± 9
Sinus rhythm (%) 24 (100%) 19 (95%) 19 (100%) 20 (100%)
QRS duration (ms) 108± 22 102± 21 114± 24 99± 16∗
Left bundle-branch block 3 (12%) 2 (10%) 3 (16%) 1 (5%)
Exercise capacity
Peak systolic BP (mm Hg) 130± 24 140± 18 138± 24 155± 18∗
Peak heart rate (bpm) 138± 19 146± 13 132± 22 135± 18
VO2 peak (ml/kg/min) 18.2± 6.2 20.6± 2.8 19.3± 6.8 23.1± 5.2∗
VO2 peak (% of predicted) 54± 20 60± 8 58± 20 69± 16∗
VE/VCO2 slope 31.0± 10.9 26.4± 6.6 29.4± 7.7 24.4± 3.7∗∗
Biomarker testing
Sodium (mmol/L) 140± 2 142± 2∗ 140± 2 141± 3
Creatinine (umol/L) 88± 19 104± 27∗ 80± 16 92± 27
GFR (ml/min) 86± 25 71± 18∗ 92± 25 84± 27
BNP (ng/L) 787 [376–1264] 375 [229–933] 172 [56–377] 25 [13–55]∗∗
Hs-cTNT (ng/L) 17.5 [7.0–76.7] 9.5 [3.2–18.5]∗ − −
Hs-cTNT > 13.5 ng/L 15 (62%) 8 (40%) − −
Troponin I > 0.03 µg/L 9 (37%) 4 (20%) − −
Galectin-3 (µg/L) 3.6 [0.4–5.1] 1.5 [0.2–4.5] − −
Pharmacotherapy
ACEI/ARB 21 (87%) 19 (95%) 16 (84%) 19 (95%)
ACEI/ARB ≥ 50% 5 (21%) 5 (25%) 10 (53%) 12 (60%)
Beta-blockers 21 (87%) 20 (100%) 20 (100%) 19 (100%)
Beta-blockers ≥ 50% of r.d. 6 (25%) 5 (25%) 18 (95%) 16 (80%)
Furosemide 22 (92%) 18 (90%) 15 (79%) 13 (65%)
Furosemide ≥ 40mg/d 16 (67%) 14 (70%) 11 (58%) 8 (40%)
Intravenous diuretics 10 (42%) 3 (15%) 0 0
Spironolactone 21 (87%) 14 (70%) 14 (74%) 9 (45%)
Inotropes 5 (21%) 1 (5%) 0 0
*, **, *** denotes p<0.05, p<0.01, p<0.001; BP = blood pressure; HF = heart failure.
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Table 13: Comparison of baseline variables with regard to LVRR—part II
Variable
Baseline data Data at 1 year
LVRR− LVRR+ LVRR− LVRR+
n = 24 n = 20 n = 19 n = 20
Echocardiography
LVEDD (mm) 69± 6 69± 7 67± 7 58± 5∗∗
LVEDD indexed (mm/m) 40± 3 38± 3 39± 4 33± 2∗∗∗
LV septum thickness (mm) 9± 1 9± 2 9± 1 9± 1
LV ejection fraction (%) 24± 8 22± 6 26± 6 42± 6∗∗∗
Restrictive LV filling pattern 11 (46%) 6 (30%) 2 (11%) 0
E/E’ ratio 13.7± 5.5 12.5± 5.2 12.0± 3.6 8.2± 2.8∗∗
LA diameter (mm/m) 27± 3 26± 4 25± 3 21± 3∗∗
LA volume index (ml/m2) 54± 21 43± 16 43± 16 30± 7∗∗
MR grade ≥3 of 4 16 (67%) 9 (42%) 10 (53%) 0∗∗∗
RVEDD (mm) 29± 6 29± 6 25± 4 26± 3
TAPSE (mm) 17± 4 18± 5 21± 3 22± 4
CMR
LVEDV (ml/m2) 147± 45 132± 35 113± 26 71± 12∗∗∗
LV ejection fraction (%) 22± 10 21± 10 28± 5 42± 5∗∗∗
LV mass (g/m2) 106± 26 105± 28 86± 14 80± 18
RVEDV (ml/m2) 80± 33 75± 27 66± 22 60± 13
RV ejection fraction (%) 23± 9 24± 8 35± 8 45± 7∗∗
LGE present 18 (75%) 12 (60%) 7 (58%) 8 (44%)
LGE extent (g) 9.4 [2.4–16.4] 2.9 [0–8.4]∗ 4.6 [0–10.3] 0 [0–4.1]
Indexed LGE extent (%) 4.3 [1.1–7.8] 1.4 [0–4.3]∗∗ 2.2 [0–7.3] 0 [0–2.5]
Myocardial edema ratio 1.4± 0.2 1.6± 0.4∗ 1.2± 0.3 1.3± 0.2
Myocardial edema ratio > 1.9 0 4 (20%)∗ 0 0
Early enhancement (%) 25.5 [17.9–42] 15.6 [6.6–36.9] − −
Early enhancement > 45% 4 (18%) 3 (15%) − −
Biopsy findings
Myocardial inflammation 5 (21%) 10 (50%)∗ − −
Virus positive (%) 17 (71%) 12 (60%) − −
Parvovirus B19 positive 17 (71%) 10 (50%) − −
Parvovirus B19 (copies/µg) 120 [0–547] 72 [0–922] − −
Other viruses 1 (4%) 4 (20%) − −
Extent of fibrosis 15.4± 8.2 13.5± 6.9 − −
*, **, *** denotes p<0.05, p<0.01 and p<0.001, respectively
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Table 14: Association between variables recorded at 3 and 6 months of follow-up and
LVRR at 1 year of follow-up.
Variable
Data at 3 months Data at 6 months
LVRR− LVRR+ LVRR− LVRR+
n = 20 n = 20 n = 19 n = 20
NYHA I 2 (10%) 6 (30%)∗∗ 3 (16%) 9 (45%)∗∗
II 11 (55%) 14 (70%) 9 (47%) 11 (55%)
III 17 (35%) 0 7 (37%) 0
IV 0 0 0 0
ACEI/ARB 17 (85%) 19 (95%) 16 (84%) 19 (95%)
ACEI/ARB ≥ 50% of r.d. 7 (35%) 7 (35%) 6 (32%) 9 (45%)
Beta-blockers 20 (100%) 20 (100%) 20 (100%) 19 (100%)
Beta-blockers ≥ 50% of r.d. 10 (50%) 9 (45%) 14 (74%) 13 (65%)
Furosemide 16 (80%) 18 (90%) 15 (79%) 16 (80%)
Spironolactone 15 (75%) 15 (75%) 14 (74%) 10 (50%)
Furosemide ≥ 40mg/d 12 (60%) 15 (75%) 12 (63%) 11 (55%)
Body mass index (kg/m2) 26 ± 5 26 ± 3 27 ± 4 26 ± 4
Systolic BP at rest (mmHg) 110 ± 14 112 ± 11 114 ± 10 112 ± 12
Systolic BP peak† (mmHg) 129 ± 21 150 ± 19∗∗ 133 ± 19 152 ± 20∗∗
Heart rate at rest (bpm) 82 ± 14 72 ± 11∗ 74 ± 15 70 ± 12
Heart rate peak† (bpm) 133 ± 19 145 ± 18 133 ± 22 136 ± 19
Sinus rhythm 20 (100%) 19 (95%) 19 (100%) 20 (100%)
QRS duration (ms) 110 ± 24 99 ± 17 110 ± 20 99 ± 16
Left bundle-branch block 3 (15%) 1 (5%) 3 (16%) 1 (5%)
LVEDD (mm) 69 ± 8 64 ± 8 67 ± 9 61 ± 6∗∗
LVEDD indexed (mm/m) 40 ± 4 36 ± 4∗∗ 39 ± 4 34 ± 3∗∗∗
LV septum thickness (mm) 9 ± 1 9 ± 2 9 ± 1 8 ± 1
LV ejection fraction (%) 26 ± 7 30 ± 7 28 ± 7 37 ± 10∗∗
Restrictive LV filling 8 (40%) 0∗∗ 2 (10%) 0
E/E’ ratio 13.4 ± 7.4 8.8 ± 3.3∗ 12.2 ± 3.7 8.0 ± 2∗∗
LA diameter (mm/m) 25 ± 3 22 ± 3∗∗ 26 ± 4 21 ± 3∗∗∗
LA volume index (ml/m2) 46 ± 17 34 ± 10∗ 45 ± 17 30 ± 8∗∗
Mitral regurgitation ≥3 of 4 10 (50%) 3 (15%)∗ 8 (42%) 1(5%)∗∗
RVEDD (mm) 27 ± 4 27 ± 3 27 ± 3 27 ± 3
TAPSE (mm) 19 ± 4 21 ± 5 21 ± 4 20 ± 4
VO2 peak† (ml/kg/min) 17.9 ± 5.5 22.2 ± 4.5∗∗ 18.0 ± 5.3 21.9 ± 3.2∗∗
VO2 peak† (% of predicted) 53 ± 19 65 ± 14∗∗ 54 ± 17 67 ± 14∗∗
VE/VCO2 slope† 30.1 ± 8.7 23.5 ± 3.2∗∗ 29.5 ± 8.8 24.5 ± 4.0∗∗
Sodium (mmol/L) 141 ± 2 140 ± 2 140 ± 2 140 ± 2
Creatinine (umol/L) 85 ± 27 91 ± 26 79 ± 16 94 ± 25∗
GFR (ml/min) 91 ± 29 84 ± 24 94 ± 28 81 ± 25
BNP (ng/L) 350 [149–731] 101 [70–196]∗∗ 244 [66–538] 53 [36–70]∗∗∗
*, **, *** denotes p<0.05, p<0.01, p<0.001; † corresponds to data obtained during exercise
testing; BP = blood pressure.
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4.8.1 CMR findings after 12 months of follow-up
A follow-up CMR was available in 30 non-transplanted individuals that did not
have implanted a metallic cardiac device. At baseline, LGE was present in 20
of 30 patients (67%) with the follow-up CMR. At 12 months, LGE persisted in
13 (43%) and disappeared in another 7 (23%). Out of 10 patients who did not
present with LGE at baseline, 8 (27%) remained without LGE but (7%) developed
a new LGE lesion. Pattern and localization of the LGE in the LV did not differ
with respect to the LVRR. Importantly, both the LGE extent and the myocardial
edema ratio decreased during the follow-up (5.5 [0-12] vs. 1.3 [0-6] g, P = 0.001;
and 1.53 ± 0.37 vs. 1.29 ± 0.25, P = 0.002; respectively). A typical finding
of a reduced LGE at the 12-months examination is presented in Figure 12. The
baseline values of the LGE extent and the myocardial edema ratio significantly
differed between the patients without and with LVRR (Table 13). On the other
hand, the absolute or relative changes in the LGE extent and myocardial edema
ratio did not differ with respect to the LVRR (absolute [relative] change; no LVRR
vs. LVRR; LGE extent, -2.7 ± 4.8 vs. -3.9 ± 5.0 % [-60 ± 48 vs. -46 ± 40 %],
P = 0.46; myocardial edema ratio; -0.17 ± 0.25 vs. -0.33 ± -0.48 [-110 ± 18 vs.
116 ± 22 %], P = 0.32).
4.9 Prediction of LVRR from baseline data
In the univariate analysis, 9 of 70 baseline variables predicted the subsequent
LVRR (Table 12). Compared with the remaining individuals, LVRR was heralded
by lower serum levels of hs-cTNT, higher plasma levels of sodium and, surprisingly,
by worse renal function. Other predictive parameters included a higher prevalence
of myocardial inflammation in biopsy and two CMR variables—a smaller extent
of LGE and a higher myocardial edema ratio.
Neither the presence of viral genomes nor the extent of fibrosis in EMB samples
were related to LVRR. A multivariate analysis identified only two independent
predictors of LVRR at baseline: a lower value of the indexed LGE extent and a
higher value of the myocardial edema ratio (Table 16). A simultaneous positivity
of both variables predicted LVRR with a sensitivity of 70% and a specificity of
78% (Table 15).
4.10 Prediction of LVRR from the follow-up data
In the univariate analysis, 15 of 60 follow-up variables predicted LVRR. These
predictors included a better exercise capacity, a lower LVEDD, a higher LV ejection
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fraction, less severe mitral regurgitation, a smaller left atrial volume and lower
values of non-invasive indicators of the LV filling pressure (E/E’ ratio, presence of
restrive mitral pattern, BNP plasma level) (Figure 13 and Table 14). Importantly,
there were no differences in the use of heart failure medication in both groups. At
3 months, the latest plasma level of BNP was the only independent predictor of
LVRR (Table 16). Specifically, BNP level < 344 ng/L predicted LVRR with a
sensitivity of 95% and a specificity of 50% (Table 15). The conventional methods
(LVEDD index and E/E’ ratio) became independent predictors of LVRR as late
as after 6 months of follow-up. Both the baseline indexed LGE extent and the
myocardial edema ratio remained independent predictors of LVRR when combined
with the BNP plasma level at 3 months or with the LVEDD index and the E/E’
ratio at 6 months (Table 16).
Figure 12: Change in the extent of LGE after 1 year with regard to LVRR
The yellow areas indicate a signal intensity >2 standard deviations above the mean
of the remote reference myocardium. Panels A and B demonstrate corresponding
short-axis slices at baseline and 12 months follow-up in a patient with LVRR.
Panels C and D show similar images in a patient without LVRR. There was a
marked reduction in the extent of LGE in the patient with LVRR but there was
virtually no change in the extent of LGE in the patient without LVRR.
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Figure 13: Longitudinal changes in LVEDD and median BNP levels in
patients with and without LVRR
Table 15: Results of receiver operator characteristics analysis with selected cut-off
points of variables predicting left ventricular reverse remodeling.
Variable Cut-off SN SP AUC [95% CI] P
BL
Indexed LGE extent (%) < 5 90 46 0.73 [0.58–0.88] 0.009
Edema ratio ≥1.30 80 44 0.67 [0.51–0.84] 0.043
Indexed LGE extent
+ edema ratio <5 and ≥1.30 70 78
3 M BNP (ng/L) <344 95 50 0.79 [0.64–0.94] 0.002
6 M
LVEDD (mm/m) <38 85 68 0.83 [0.70–0.96] 0.000
E/E’ ratio <11.7 100 53 0.82 [0.69–0.96] 0.001
BNP (ng/L) <168 95 63 0.81 [0.67–0.95] 0.001
LVEDD and E/E’ ratio <38 and <11.7 85 84
LVEDD and BNP <38 and <168 80 79
BL, 3 M and 6 M = baseline, 3 months and 6 months; AUC = area under the curve; CI =
confidence interval; P = p-Value; SN = sensitivity; SP = specificity.
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Table 16: Results of multivariate analysis showing independent predictors of
LVRR at baseline, 3 and 6 months of follow-up.
Multivariate model Odds ratio [95% CI] p Value
(1) Baseline
Indexed LGE extent† 0.67 [0.50–0.90] 0.008∗∗
Myocardial edema ratio‡ 1.45 [1.04–2.02] 0.027∗
(2) 3 months
B-type natriuretic peptide§ 0.14 [0.02–0.94] 0.042∗
(3) 6 months
LVEDD index¶ 0.73 [0.56–0.96] 0.014∗
E/E’ ratio 0.56 [0.33–0.94] 0.019∗
(4) Baseline + 3 months
B-type natriuretic peptide at 3 months§ 0.13 [0.01;0.96] 0.001∗∗
Myocardial edema ratio at baseline‡ 1.37 [1.18–1.93] 0.048∗
Indexed LGE extent at baseline† 0.75 [0.55–0.93] 0.028∗
(5) Baseline + 3 months + 6 months
E/E’ ratio at 6 months 0.45 [0.20–0.98] <0.001∗∗∗
LVEDD index at 6 months¶ 0.78 [0.59–0.95] 0.005∗∗
Indexed LGE extent at baseline† 0.69 [0.45–0.96] 0.047∗
Myocardial edema ratio at baseline‡ 1.57 [1.12–2.7] 0.027∗
† signifies odds ratio per % of LV mass; ‡, per 0.1 unit; §, per log(µg/l); ¶, per mm/m,
respectively.
Variables which were entered in the multivariate analysis:
Model 1 (baseline data): decompensated heart failure at admission, sodium plasma
level, estimated glomerular filtration rate, high-sensitivity cardiac troponin T, LGE
extent, myocardial edema ratio, presence of myocardial inflammation in biopsy
Model 2 (3-month data) : NYHA functional class, heart rate, LVEDD index, restrictive
mitral pattern, severity of mitral regurgitation, left atrial volume index, peak exercise
systolic blood pressure, peak oxygen consumption, VE/VCO2 slope, Log BNP.
Model 3 (6-month data): NYHA functional class, LVEDD index, LV ejection fraction,
E/Em, left atrial volume index, peak exercise systolic blood pressure, peak oxygen
consumption, VE/VCO2 slope, Log BNP.
Model 4 (independent predictors from model 1 and 2): indexed LGE extent, myocardial
edema ratio, Log BNP (3 months).
Model 5 (independent predictors from models 1 to 3): indexed LGE extent, myocardial
edema ratio, Log BNP (3 months), LVEDD index (6 months), E/Em (6 months).
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4.11 Prediction of adverse clinical events
Besides evaluation of LVRR at 12 months of follow-up, the patients were fol-
lowed for 25 ± 9 months for occurrence of adverse clinical events. During this
period, 8 patients (18%) were readmitted for decompensation of heart failure,
4 (9%) received a ventricular assist device, 4 (9%) underwent an urgent heart
transplantation and another 4 (9%) died. The causes of the deaths included rapid
progression of multiorgan failure (n=1), sudden cardiac death (n=1) and fatal
complications related to the implantation of the ventricular assist device (n=2).
Twelve patients (27 %) reached a composite clinical end point which was de-
fined by occurrence of any of the above events, order by their severity: cardiac
death (n = 4), urgent heart transplantation (n = 4) and hospitalization for de-
compensation of heart failure (n = 4). Two of the transplanted patients and two
of the deceased patients had implanted a ventricular assist device. By univari-
ate analysis, the composite clinical endpoint was associated with a higher NYHA
class, increased BNP levels, presence of LGE, greater extent of LGE and increased
baseline concentrations of hs-cTnT.
The time of the occurrence of the events, with regard to the baseline presence
of LGE is depicted on the Kaplan-Meier plot on the Figure 14. In Cox’s multi-
variate regression models only the increased hs-cTnT concentration remained an
independent predictor of the end point.
Unfortunately, the study was underpowered to identify any predictors of a com-
posite “hard” clinical endpoint consisting of mortality, urgent heart transplanta-
tion or implantation of mechanical ventricular assist device, not considering the
hospitalization for heart failure. An implantable cardioverter-defibrillator for pri-
mary prevention of sudden arrhythmic death was implanted in 12 (27%) patients.
Only one of them had an adequate shock for ventricular fibrillation at 1.5 years of
follow-up. Additional 4 patients with left bundle-branch block received a biven-
tricular pacemaker for resynchronization therapy (at 12, 14, 19 and 21 months of
follow-up).
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Table 17: Univariate analysis of the variables associated with the composite
end point of cardiac death, urgent heart transplanation, or hospitalization for
worsening of heart failure.
Variable HR [95% CI] p Value
Male 1.3 [0.4–4.3] 0.72
Age (per year) 0.96 [0.9–1.0] 0.14
Serum creatinine (per mg/dL) 0.99 [0.9–1.0] 0.49
NYHA class 2.2 [1.1–4.8] 0.028∗
B-type natriuretic peptide (per log(ng/L)) 2.7 [1.2–6.2] 0.022∗
High-sensitivity troponin T (per log(ng/L)) 2.2 [1.4–3.5] 0.001∗∗
High-sensitivity troponin T > 13.5pg/L 5.1 [1.1–23] 0.035∗
Idexed LGE extent (per % of LV mass) 1.1 [1.0–1.2] 0.008∗∗
LGE present 6.3 [0.8–49] 0.044∗
Edema ratio (per unit) 0.5 [0.1–3.6] 0.46
Early gadolinium enhancement (per %) 1.0 [1.0–1.0] 0.33
Pericardial effusion (per ml) 2.5 [0.8–8.2] 0.13
Myocardial inflammation in biopsy 1.3 [0.4–4.2] 0.64
Viral genoma in biopsy 1.6 [0.5–5.0] 0.44
Extent of fibrosis in biopsy (per %) 1.0 [0.9–1.1) 0.27
HR = hazard ratio; CI = confidence interval.
Table 18: Univariate and multivariate predictors of the composite end point of cardiac
death, urgent heart transplanation, or hospitalization for worsening of heart failure.
Variables Univariate analysis Cox’s regression models
HR [95% CI] p Value HR (95% CI) p Value
Gender (male) 1.3 [0.4–4.3] 0.72
Age (years) 0.96 [0.9–1.0] 0.14
Creatinine (mg/dL) 0.99 [0.9–1.0] 0.49
NYHA class 2.2 [1.1–4.8] 0.028∗
BNP (per log(ngL)) 2.7 [1.2–6.2] 0.022∗ 8.3 [0.7–97.2] 0.09
Hs-TnT (per log(ngL)) 2.2 [1.4–3.5] 0.001∗∗ 5.3 [1.3–21.3] 0.019∗
Inflammation in EMB 1.3 [0.4–4.2] 0.64
Extent of fibrosis in EMB (%) 1.0 [0.9–1.1] 0.27
Extent of LGE (% of LV mass) 1.1 [1.0–1.2] 0.008∗∗ 3.1 (0.9–11.0) 0.066
HR = hazard ratio; CI = confidence interval.
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Figure 14: Kaplan-Meier analysis of a mid-term freedom from a composite
endpoint of adverse clinical events according to the baseline presence of LGE
The figure shows Kaplan-Meier freedom from a composite endpoint of death related
to heart failure, urgent heart transplantation and readmission for worsening of
heart failure, using the baseline presence of LGE as the strata. LGE-/+ signifies
absence/presence of LGE at the baseline examination.
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5 Discussion
5.1 The main contribution of this work
This is the first study that systematically evaluated use of a novel multisequential
CMR protocol for assessment of pathophysiological processes in the individuals
with new-onset DCM. In addition, our study was able to demonstrate prognostic
value of the pathological CMR findings with regard to LVRR. One of the main
strengths of the study was the complexity of the collected data: besides the CMR
scans, we had available histopathological and immunohistochemical assessment of
the myocardial tissue; biomarker data reflecting hemodynamic status and activity
of myocardial necrosis; a thorough clinical assessment which included functional
exercise testing; and a rigorous mid-term clinical follow-up. At last, serial CMR
scans enabled to intercept evolution of the myocardial pathological processes and
its relationship to the LVRR.
5.2 Major findings
Among the extensive data obtained in the study there are several findings that
should be highlighted:
1. Myocardial inflammation was a common finding in the individuals with new-
onset DCM, though the inflammation had generally a low activity.
2. The overall performance of CMR for detection of myocardial inflammation
was rather modest. LGE was a sensitive sign for myocardial inflammation,
however it was also a hallmark of more advanced heart failure. Myocardial
early enhancement and pericardial effusion were specific but uncommon find-
ings. Imaging of myocardial edema by T2-weighted imaging was not useful
for the diagnosis.
3. The concurrent use of CMR, EMB and novel cardiac biomarkers provided
new insights into pathophysiology of LGE in new-onset DCM. In particu-
lar, we demonstrated that in new-onset DCM the presence of LGE may be
equally attributed to myocardial inflammation and to an ongoing myocar-
dial necrosis damage due to the LV hemodynamic overload. Importantly, in
some patients the LGE had receded or even disappeared over one year and
this receding of the LGE was paralleled with the LVRR.
4. A lower extent of LGE and a higher myocardial edema ratio were indepen-
dent baseline predictors of LVRR at 12 months. In fact, at baseline these
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CMR markers outperformed BNP, EMB and conventional methods for pre-
diction of LVRR. Although at a later stage of the disease the actual BNP
levels, LVEDD and E/E’ ratio became the strongest predictors of the LVRR,
the baseline LGE and the myocardial edema ratio retained their independent
predictive value. In addition, the presence of LGE was also a strong pre-
dictor of future adverse clinical events, such as cardiac death, urgent heart
transplantation and rehospitalization for heart failure.
5.3 CMR for detection of myocardial inflammation
The value of CMR for detection of clinically suspected acute myocarditis has been
repeatedly demonstrated (Friedrich et al. 2009). But, similar data are lacking
for the patients with new-onset DCM who have no clinical signs of myocarditis.
Recently, Voigt and colleagues evaluated the diagnostic performance of CMR for
detection of immunohistologically confirmed myocardial inflammation in 23 DCM
patients with a history of heart failure longer than 3 months (Voigt et al. 2011).
They reported the overall sensitivity, specificity and diagnostic accuracy of CMR
of 75%, 73% and 74%, respectively. These results are similar to the overall
sensitivity, specificity and accuracy of 67% , 85% and 79% found in our study.
In contrast to the study by Voigt and several other studies in patients with acute
myocarditis, we found that the T2-weighted imaging did not add any diagnostic
value to the CMR protocol. Moreover, we found rather a modest diagnostic value
of the myocardial early enhancement technique. The limited performance of the
two CMR techniques found by our study could be explained by the fact that
the target pathophysiological processes (myocardial edema, hyperperfusion and
capillary leakage) were less expressed in our patients than in an acute myocardial
inflammation (De Cobelli et al. 2006, Friedrich et al. 1998).
Gutberlet and colleagues observed LGE only in 24% of patients with clinically
suspected "borderline" myocarditis and preserved LV dysfunction (Gutberlet et al.
2008). The LGE had 80% specificity for myocarditis. In contrast, the LGE was
present in 67% of our patients (who had also mostly low-activity myocarditis but
with severe LV dysfunction), though the finding had only 44% specificity for my-
ocarditis. The higher prevalence of LGE found in the patients with LV dysfunction
and the lower specificity of this finding for myocarditis could be explained by the
fact that the LGE in DCM may also reflect pathophysiological processes that are
related to the heart failure itself. In this regard, the increased levels of BNP and
cardiac troponin in our patients with LGE support a previously proposed hypoth-
esis that an increased wall stress in the overloaded dilated LV may lead to relative
myocardial ischemia, which in turn may result to myocyte necrosis (Alter et al.
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2007). In fact, by combining the results of CMR, EMB and cardiac biomarkers
we were able to show that the LGE in the patients with new-onset DCM accounts
roughly by an equal part for myocardial inflammation and by an equal part for the
hemodynamic stress. Furthermore, in DCM patients the LGE seem to be more
common in an earlier stage of the disease (56% in the study by Voigt and 67% in
our study) than at a chronic stage (39–41% Lehrke et al. (2011), Wu et al. (2008)).
This could be explained by a natural or pharmacotherapy-induced resolution of
either the myocarditis or by the resolution of the stress-related myocardial injury.
Finally, the myocardial injury, regardless of the etiology, can recede or eventually
it can heal with a fibrotic scar. The scar may then appear as LGE. Thus, the
pathophysiology of LGE in DCM must be interpreted in the context of the disease
duration and the hemodynamic status.
5.4 CMR for predicting LVRR and clinical outcome in
new-onset DCM
The concept of LVRR was introduced by Dec & Fuster (1994). A larger study by
Steimle et al. (1994), conducted before the era of beta-blockers, observed LVRR in
27% of patients with DCM. Over time, advances in heart failure pharmacotherapy
have increased the incidence of LVRR in general heart failure population (Bink-
ley et al. 2012, Wilcox et al. 2012) and also in the subpopulation of new-onset
DCM (McNamara et al. 2011). In the Intervention in Myocarditis and Acute Car-
diomyopathy trials IMAC-1 and IMAC-2 the incidence of LVRR reached 56% at
12 months and 70% at 6 months, respectively (McNamara et al. 2001, 2011). In
agreement with the IMAC-1 study we observed LVRR in 45% patients.
In the study by Steimle the LVRR was associated with a shorter symptom
duration and less severe hemodynamic decompensation (Steimle et al. 1994). In-
terestingly, the finding of myocarditis in EMB (using the Dallas criteria) did not
predict the LVRR. In line with Steimle, in univariate analysis we found significant
association between biopsy-confirmed myocardial inflammation and LVRR but the
predictive value of this finding was not confirmed in the multivariate models. In
the IMAC-2 trial, the LVRR was associated with a lower NYHA functional class,
lower LVEDD and a higher systolic blood pressure. However, none of the variables
were robust enough to aid the clinical decision making (McNamara et al. 2011).
In our study we introduced novel predictors of LVRR that are much more robust
than those previously reported, in particular the variables derived from CMR and
serial BNP testing. In addition, we evaluated the predictors of LVRR not only
at baseline but also longitudinally. As a result, we could identify specific cut-off
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points for each follow-up period and showed that the novel predictors provided an
earlier prediction of LVRR than the conventional methods.
Previously, the prognostic value of CMR was investigated mostly in the patients
with long-term established diagnosis of DCM (Assomull et al. 2006, Wu et al.
2008). The study by Leong and colleagues was the first to focus on the newly
manifested DCM (Leong et al. 2012). The authors demonstrated strong negative
correlation between the extent of LGE and improvement of LV systolic function.
Unfortunately, the study was limited by the fact that the improvement in LV was
defined by somewhat clinically irrelevant 5% increase in the LV ejection fraction.
Moreover, the study by Leong excluded all individuals with possible myocarditis
(which was defined by abnormal troponin or evidence of myocardial edema on T2-
weighted imaging), but tachycardia-induced cardiomyopathy was not considered
to be an exclusion criterion.
In our study, we excluded only individuals with suspected tachycardia-induced
cardiomyopathy and alcoholic cardiomyopathy because they are recognized as
highly reversible disease entities. We found no good reason not to recruit troponin
I positive individuals with new-onset DCM who represented almost one third of
our consecutive patients. We believe that our inclusion criteria, the definition of
LVRR and the structured one year follow-up better support the applicability of
our results in the clinical practice.
Importantly, extent of myocardial damage, as assessed by CMR, not only pre-
dicts the LVRR but it is a robust predictor of mortality in inflammatory (Wilcox
et al. 2012) as well as in idiopathic DCM (Steimle et al. 1994, Binkley et al. 2012).
Our study expands the available evidence by confirming the prognostic role of
LGE also in the patients with new-onset DCM. All these data justify the routine
use of CMR in patients with newly diagnosed DCM.
5.5 Pathophysiology of LVRR
Despite the long-term recognition of the phenomenon of LVRR a little is known
about the underlying pathophysiology, especially if the LVRR occurs sponta-
neously. Though the LVRR is primarily defined as a decrease in the LV volume
and improvement of the contractile function, complex structural and functional
changes have been described at the cellular and tissue level (Koitabashi & Kass
2012). For certain etiologies of DCM, the LVRR may occur once the triggering
insult is resolved. Currently, there are three major etiologies of DCM that are
associated with a high rate LVRR and even with full LV recovery. These include
DCM caused by tachycardias (above all, by atrial fibrillation), by toxic insults and
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by myocardial inflammation. The first two can be readily diagnosed by clinical
presentation and medical history. The later can be detected by endomyocardial
biopsy or less reliably by CMR. In addition, we have demonstrated by a repeated
CMR, that the LVRR parallels resolution of the initial tissue pathology.
5.6 Therapeutic implications
Determining the etiology of DCM in an affected individual may be clinically rele-
vant. The patients with inflammatory DCM seem to have somewhat better prog-
nosis than the patients with idiopathic DCM, though our study was unable to
confirm similar observations (Givertz & Mann 2013).
Furthermore, besides naturally more favorable course of the disease, the pa-
tients with inflammatory DCM may receive a specific therapy targeting inflam-
mation on top of the standard management of heart failure. Improvement in LV
ejection fraction by >15-20% have been reported in several smaller case series
using immunosuppression, immunoadsorption or anti-viral therapy (Kindermann
et al. 2012). However, no study assessed mortality or morbidity benefits of such
treatments in patients with DCM.
One of the reasons for the lack of larger studies on inflammation-targeted treat-
ment in DCM is the difficulty to select appropriate candidates for the treatment.
Screening for inflammatory DCM solely by EMB may be limited by its low di-
agnostic yield. In fact, Frustaci had to perform 500 biopsies to identify only 85
(17%) potential candidates for immunosuppressive therapy (Frustaci et al. 2009).
The proportion was even lower (3%) in the study of Maisch et al. (2007). In this
context, CMR may probably not fully replace EMB in establishing the diagnosis
before initiation of a specific treatment; however, the LGE could serve as a selec-
tion criterion for referring patients with new-onset DCM for EMB. Of note, in our
study group such approach would prevent many unnecessary biopsies with a high
negative predictive value.
The role of CMR (specifically the extent of LGE) to predict response to phar-
macotherapy in chronic heart failure patients was reported by Bello and colleagues
already in 2003 (Bello et al. 2003). It was the first study that opened the door
to the personalized medicine in this field. Improved prediction of clinical outcome
among individuals with new-onset DCM might be helpful for the cost-effective
use of implantable cardioverter-defibrillators in the primary prevention of sudden
cardiac death and it could also be used for optimal timing of referral to heart
transplantation. Therefore, we propose to include CMR into the routine baseline
assessment of all patients with new-onset DCM.
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5.7 Study limitations
The relatively small size of the study sample may have influenced the power of
the statistical analysis. To prevent overfitting, the multivariate regression models
were restricted to a maximum of 2 independent variables, because the total number
of the followed events was <30 (Peduzzi et al. 1995). The main reason for the
restricted study size was its complex design. Besides a thorough clinical and
laboratory investigation, repeated CMR exams and a detailed clinical follow-up
the patients underwent an invasive procedure - EMB.
The EMB was performed only from the right-ventricular side of the interven-
tricular septum. This could have introduced a sampling bias. The diagnostic yield
could have been improved by targeting the biopsy to the sites with a pathological
finding on CMR or by harvesting the samples from the LV cavity (Mahrholdt et al.
2004). On the other hand, these alternative approaches of EMB could have jeop-
ardized the patients’ safety and they would have made the procedure substantially
more complex. In fact, we have demonstrated that the prevalence of myocarditis
detected by right ventricular approach was not dependent on the localization of
the LGE in the LV. This finding implies that our EMB results might not have
been significantly influenced by the chosen approach.
For evaluation of the patients’ hemodynamic status we used BNP levels as a
surrogate of the LV filling pressure. Although the biomarker is routinely used
for this purpose in the clinical practice, an invasive measurement of the filling
pressures would be more appropriate. On the other hand, this would require
either right heart catheterization or an additional LV catheterization through an
arterial approach, thus further increasing the risk of complications.
We used one of several previously proposed immunohistochemical arbitrary def-
initions of myocardial inflammation. Various other definitions have been used by
other investigators. In fact, the lack of the standardization of the immunohisto-
chemical criteria might cause a comparison between future studies problematic.
For evaluation of global early enhancement we used a method proposed by
Laissy et al. (2002). We preferred this approach mainly because of an extensive
experience with this technique in our institution. Although this technique has
been validated against EMB, recently a consensus of experts suggested to use a
slightly different, more specific, method for the evaluation of early enhancement.
We evaluated the presence and extent of LGE in the LV irrespective of its
pattern and localization in the LV. In fact, various patterns a localization of the
LV could have represented a different underlying pathology, which in turn could
be related to a different clinical outcome. Nevertheless, we have demonstrated
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that the presence of LGE per se is an independent marker of LVRR and adverse
clinical events.
Finally, although the used definition of LVRR has been used by previous inves-
tigators, such definition is rather specific for patients with severe LV dysfunction.
Different cut-offs might be suitable for different populations.
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6 Conclusions
In patients with new-onset DCM, CMR has suboptimal accuracy for detection
of myocardial inflammation mainly because the activity of the inflammation is
generally low. On the other hand, CMR can be used for noninvasive evaluation
of hemodynamic stress and extent of myocardial damage. LVRR is relatively
common, but complete recovery of the left ventricular dysfunction is rare. The
pathological CMR findings, specifically the extent of LGE and the myocardial
edema ratio provide at a baseline examination a better prediction of the LVRR
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